

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A01N 63/00, A61K 48/00, C07H 21/02, 21/04, C07K 1/00, 14/00, 17/00, C12N 15/00, C12P 21/06, G01N 33/53		A1	(11) International Publication Number: WO 95/31904 (43) International Publication Date: 30 November 1995 (30.11.95)
(21) International Application Number: PCT/US95/06683 (22) International Filing Date: 24 May 1995 (24.05.95) (30) Priority Data: 08/248,355 24 May 1994 (24.05.94) US (60) Parent Application or Grant (63) Related by Continuation US 08/248,355 (CIP) Filed on 24 May 1994 (24.05.94) (71) Applicant (for all designated States except US): THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK [US/US]; West 116th Street and Broadway, New York, NY 10027 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): GOFF, Stephen, P. [US/US]; 66 Windsor Road, Tenafly, NJ 07670 (US). KALPANA, Ganjam, V. [IN/US]; 107 Winchester Drive, Yonkers, NY 10710 (US).		(74) Agent: WHITE, John, P.; Cooper & Dunham L.L.P., 1185 Avenue of the Americas, New York, NY 10036 (US). (81) Designated States: AU, CA, JP, MX, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published With international search report.	
(54) Title: METHODS FOR THE IDENTIFICATION OF HIV ANTI-VIRAL AGENTS CAPABLE OF ABROGATING INTEGRASE INTERACTOR PROTEIN BINDING			
(57) Abstract This invention provides an isolated nucleic acid encoding an integrase interactor (1) gene (ini-1). The invention further provides a purified polypeptide comprising naturally-occurring ini-1. The invention also provides for the purified polypeptide possesses part or all the amino acid sequence of human ini-1 as shown in figure 4, or any naturally occurring allelic variant thereof. The invention further provides methods of determining whether a compound is capable of interfering with the formation of a complex between a retrovirus integrase protein and an ini-1 protein. Finally, the invention provides for a method of disrupting a retrovirus life cycle in a mammal which comprises administering to the mammal a compound which is capable of disrupting a retrovirus integrase protein-ini-1 protein interaction so as to thereby disrupt the retrovirus life cycle.			

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LJ	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

"METHODS FOR THE IDENTIFICATION OF HIV ANTI-VIRAL AGENTS CAPABLE OF ABROGATING INTEGRASE INTERACTOR PROTEIN BINDING"

5

This application is a continuation-in-part of U.S. Serial No. 08/248,355 filed May 24, 1994, the contents of which are incorporated by reference. The invention
10 disclosed herein was made with Government support under Grant No. A124845 from the National Institute of Allergy and Infectious Disease. Accordingly, the U.S. Government has certain rights in this invention.

15 Throughout this application, various references are referred to by author and year in parentheses. Disclosures of these publications in their entireties are hereby incorporated into this application to more fully describe the state of the art to which this
20 invention pertains. Full bibliographic citation for these references may be found at the end of this application, preceding the claims.

Background of the Invention

25

In the first few hours after entry into a host cell, retroviruses direct the reverse transcription of the RNA genome into DNA, and then the insertion of that DNA into the host genome to form the integrated provirus
30 (Goff, 1992; Weiss et al., 1984). The integration reaction is essential for the successful expression of the viral DNA to give rise to progeny virus, and is responsible for the ability of the virus to persist in the infected cell. The reaction is a highly efficient
35 and orderly process. Specific inverted repeat sequences at the termini of the linear viral DNA, required in *cis*, are joined to the host DNA. The reaction is associated with specific alterations at the junctions: a small number of base pairs, usually two,

-2-

are lost from each of the termini of the unintegrated viral DNA, and a small number of base pairs initially present only once at the target site are duplicated so as to flank the integrated provirus.

5

A single virally encoded enzyme, integrase (IN), is required for the establishment of the integrated provirus. This enzyme is encoded by the 3' portion of the *pol* gene (Schwartzberg et al., 1984) and is packaged inside the virion particle in the course of virion assembly. During the early stages of infection, the protein remains associated with the viral nucleic acid in a nucleoprotein complex (Farnet and Haseltine, 1991) and performs several specific reactions: first, the 3' termini of the viral DNA are cleaved to produce recessed 3'OH ends, and second, the two newly generated 3' termini are joined to the 5' phosphates on each strand of the target sequence in a concerted strand transfer reaction (Fujiwara and Mizuuchi, 1988). Only one strand of the viral DNA at each terminus is joined to each strand of the target DNA. The positions of attack by each 3' OH end on the two target DNA strands are staggered, such that the initial product contains gaps; host repair enzymes are thought to be responsible for removing unpaired bases, filling in gaps, and ligating the second strand. These repair steps result in the formation of the target site duplication flanking the provirus.

It is possible that some host proteins are directly involved in promoting the integration reactions occurring after viral infection. Although recombinant integrase preparations can carry out all the steps known to be required for processing and joining the viral DNA (Bushman and Craigie, 1991; Bushman et al., 1990; Craigie et al., 1990; Katz et al., 1990), some aspects of the reaction are not fully recapitulated in

-3-

vitro. For example, the isolated proteins show only very low specific activity for both cutting and joining of DNA (Bushman et al., 1990; Craigie et al., 1990). Furthermore, joining reactions carried out with
5 oligonucleotide substrates for some viruses result in the transfer of only one 3'OH to the target DNA yielding a Y structure, rather than the concerted transfer of two 3'OH termini to the target (Bushman et al., 1990). These inadequacies of the in vitro systems
10 may reflect problems with proper oligomerization of the IN protein, or with the absence of stimulatory cofactors. For some viruses, host proteins might be responsible for stimulation of the overall reaction in vivo, and, especially, for the concerted integration of
15 the two termini at a single locus.

Integration of retroviral DNA occurs on many chromosomes and with no apparent local sequence specificity (Dhar et al., 1980; Hughes et al., 1978;
20 Shimotohno and Temin, 1980; Shoemaker et al., 1981). Several studies, however, suggest that there may be preferred sites for integration. Proviral DNAs established by infection, rather than by transfection with cloned DNAs, seem to be more highly and
25 consistently transcribed, implying that integration sites are selected from transcriptionally active areas of the genome (Hwang and Gilboa, 1984). A significant bias for insertions into open chromatin was detected at high frequency insertion near DNase hypersensitive
30 sites (Rohdewohld et al., 1987; Vijaya et al., 1986) and into transcriptionally active regions (Scherdin et al., 1990). In addition, there may be a small number of "hot spots", or preferred sites, which are frequently targeted (Shih et al., 1988). Measurements
35 of the frequency of insertional inactivation into particular genes have been shown to give fewer events than predicted, suggesting that there may be "cold

-4-

spots" as well (King et al., 1985; Varmus et al., 1981). In vitro studies of the integration into SV40 minichromosomes showed that the origin region and linker regions between the nucleosomes tended to exclude insertions, while nucleosomal regions were efficiently targeted; phasing of the insertions in the chromatin could be observed, with a 10-bp periodicity (Pryciak et al., 1991). These results suggest that the presence of DNA binding proteins and histones on DNA can significantly perturb the target choice.

Many of the features of retroviral integration are similar to those associated with transposition of eucaryotic and prokaryotic mobile elements. Analogous studies in various retrotransposon systems also suggest that target sites for integration are non-random. The Ty elements in yeast have been shown to exhibit significant target site biases; Ty1 insertions tend to cluster near the 5' end of some target genes (Natsoulis et al., 1989) and within 400 bp of tRNA genes (Ji et al., 1993), and Ty3 insertions are highly restricted to specific positions relative to polymerase III promoters (Chalker and Sandmeyer, 1990; Chalker and Sandmeyer, 1992). In these cases the integration events are not thought to be affected by the sequence itself or by transcriptional activity, but rather are more likely to be profoundly restricted by host chromosomal proteins, with the potential candidates for the target proteins being the TFIIIB or TFIIIC transcription factors bound to the promoter (Sandmeyer et al., 1990).

The identification of host proteins that might target proviral integration, stimulate integration activity, or affect the incoming retroviral DNA in other ways would provide an important lead into new areas of research. In an attempt to find such proteins, the yeast two hybrid system has been used (Fields et al.,

-5-

U.S. Patent No. 5,283,173) to screen a cDNA library for proteins that interact with the HIV-1 IN. The search resulted in the recovery of a single novel gene, termed *ini-1* for integrase interactor 1. The predicted amino acid sequence of the *ini-1* protein shows an unexpected sequence similarity to SNF5, a yeast transcriptional activator required for the high-level expression of many genes (Laurent et al., 1990). The product of the *ini-1* gene may serve as an internal receptor for the HIV-1 IN, and may be responsible for targeting integration to active regions of the chromosome.

Summary of the Invention

5 This invention provides an isolated nucleic acid encoding an integrase interactor 1 gene (ini-1). The invention further provides a purified polypeptide comprising naturally-occurring ini-1. The invention also provides for the purified polypeptide possesses part or all the amino acid sequence of human ini-1 as shown in Figure 4 or any naturally occurring allelic variant thereof. The invention further provides methods of determining whether a compound is capable of interfering with the formation of a complex between a retrovirus integrase protein and an ini-1 protein.

10

15 Finally, the invention provides for a method of disrupting a retrovirus life cycle in a mammal which comprises administering to the mammal a compound which is capable of disrupting a retrovirus integrase protein-ini-1 protein interaction so as to thereby disrupt the retrovirus life cycle.

20

Brief Description of the Figures

Figure 1. Interaction of IN mutants with *ini-1*. Bars in the diagram indicate the regions retained in various GAL4DB-IN mutants tested for their ability to interact with a GAL4AC-*ini-1* fusion in the yeast strain GGY1::171. Yeast were cotransformed with plasmids encoding each GAL4DB fusion and GAL4AC-*ini-1* and assayed for the production of β -galactosidase. Deletions pMAA18-273 (Kalpana and Goff, 1993) were tested for IN-IN interaction in the context of GAL4AC fusions along with a GAL4DB-IN fusion. The rest of mutants were tested for IN-IN interactions when fused to either GAL4DB or GAL4AC and against a partner containing either the same mutant or the wild-type IN; the indicated result was obtained in all these settings. Gray bars indicate the GAL4 portion of the fusion protein; black portions indicates the IN portion; the blank portion of the bar indicates the deleted portion. The substitution mutations are indicated by the residues on top of the relevant bar. The residues are H = His, C = Cys, D = Asp, E = Glu, V = Val, N = Asn and S = Ser. The deletion junctions are indicated by the residue at the junction. '++' = dark blue; '+' = blue; '-' = white colony phenotype in the X-Gal assay.

Figure 2A. Northern analysis of human tissues. Northern blot probed with *ini-1* cDNA insert isolated from pD2.1. Each lane contains about 2 ug of poly(A)-selected mRNA. Lane 1: peripheral blood lymphocytes; 2: colon; 3: small intestine; 4: ovary; 5: testis; 6: prostate; 7: thymus; 8: spleen.

Figure 2B. The blot of Figure 2A after stripping and reprobing with a human actin cDNA probe.

Figure 2C. Northern analysis of human cell lines.

Northern analysis of total RNAs from human cell lines hybridized with pD2.1 probe. Lane 1 HeLa; lane 2: CB33; lane 3: Hut78. The amount of RNA loaded in each lane is not equivalent.

5

Figure 3. Overlapping cDNA clones encoding ini-1. The top bar (pD2.1) indicates the cDNA insert isolated from the yeast screen. pini-1 to 21 are from a ZAPgt11-HeLa cDNA library and pINI.gt from λ gt11-HeLa cDNA library. T7 and T3 indicates the relative position of T7 and T3 promoters with respect to cDNA inserts in the pBluescript vector.

10

Figure 4. Sequence of cDNA clone encoding ini-1 (SEQ ID NO:1). Complete sequence deduced from the overlapping ini-1 cDNA clones. The A nucleotide of the first methionine codon was considered nt#1. Amino acid residues are numbered on the right side of the diagram and nucleotides on the left (SEQ ID NO:2). Potential poly(A) addition signal AATAAA is underlined and the start and stop codons are highlighted. The poly(A) stretch in clone pINI.gt is indicated by the stretch of As in the middle of 3' non-coding region. Stop codons are indicated by '***'. The heptad repeat of leucine/valine residues are highlighted. The potential N-linked glycosylation sites are circled.

15

20

25

Figure 5A. Alignment of ini-1 with SNF5. Schematic alignment. The blocks of highest similarity are shaded, and the % identity given below. The glutamine and proline-rich regions of SNF5 are indicated.

30

Figure 5B. A central portion of the ini-1 amino acid sequence is shown aligned with that of the yeast SNF5 sequence (SEQ ID NO:3-4). Residues which are identical between the two sequences are indicated by shading. The three regions that show high degree of sequence

35

-9-

similarity between the two proteins (33-50% identity) are indicated by the bars underneath.

5 Figure 6A. Interaction of IN with GST-ini-1 in vitro. Coomassie-stained SDS/PAGE of the recombinant proteins expressed in bacteria and purified by affinity to glutathione-agarose beads.

10 Figure 6B. Interaction of IN with GST-ini-1 in vitro. The proteins bound to beads were used to specifically bind recombinant IN from a bacterial lysate, and the bound proteins were analyzed by Western blot with IN-specific antibodies. IN: lysate of bacterial cultures expressing IN; control: control bacterial lysate not
15 expressing IN. Beads: glutathione beads alone; GST: GST bound to glutathione beads; GSTIni: GST-ini-1 bound to glutathione beads. The position of the IN protein is indicated by the arrow. Molecular weight standards are indicated on the left.

20 Figure 6C. Interaction of IN with GST-ini-1 in vitro. Effect of SDS and detergents on IN-Ini interaction. IN-ini-1 complexes on beads were washed with buffer containing various concentrations of SDS and NP-40, and
25 the remaining proteins were analyzed by Western blot with antibodies to IN. The concentration of SDS and NP40 are indicated above each lane.

30 Figure 7A. Effect of salt on the interaction of IN with ini-1. Coomassie-stained gel of the bound proteins.

35 Figure 7B. Effect of salt on the interaction of IN with ini-1. Western analysis of a duplicate gel using antibodies to IN. Lanes are as in Figure 7A. Various concentration of NaCl used in the binding assays are indicated above the lanes.

-10-

Figures 8A-8D. Stimulation of IN joining activity by GSTInil and mammalian Inil extract. All joining reactions in Figures 8A-8D were carried out as described in Khavari et al., (1993) and Muchardt et al., (1993), and contained 15 ng IN per reaction. (Figure 8A) IN joining reactions carried out with or without the addition of GST and GST-InilF. Lanes 4-6 contained 50, 150, and 450 ng of GST-InilF respectively; lanes 1 and 2 contained 150 and 450 ng of GST. (Figure 8B) Effect of mammalian Inil extracts on the IN joining reactions. To isolate the SWI/SNF complex, a rat liver nuclear extract was prepared according to Gorski et. al., (1986) and fractionated on a phosphocellulose P11 column (Whatman). The 0.5M salt fraction from this column was diluted and loaded onto a DEAE-52 column (Whatman). A 0.3M KCl eluate from this column was further fractionated on an S-300 column (Pharmacia) and the excluded volume containing Brg1 and Inil was collected. Brg1 and Inil co-fractionated throughout the purification as determined by Western analysis using Brg1 and Inil antibodies. Depleted extracts were prepared by passing the Inil fraction through a Brg1 affinity column and the flow-through was collected. Lane 3 contained 1 ul of Inil extract, containing approximately 1.5 ng of Inil protein as assessed by Western analysis using Inil antibody. Lanes 4-6 contained 1, 2, and 4 ul of depleted extract, respectively. Total protein concentration in the depleted extract was approximately half that before depletion. (Figure 8C) Effect of increasing concentration of target DNA on the stimulation of joining activities. The target DNA concentration used were 10 (lanes 1, 2 and 5), 30 (lanes 3 and 6) and 90 (lanes 4 and 7) ng per 30 ul reaction, respectively. Lanes 5-7 contained 2 ul of Inil extract, containing approximately 3 ng of Inil. (Figure 8D) Effect of increasing concentration of IN

-11-

on the activity of nuclear extract. The concentration of IN used were 5 ng (lanes 2 and 6), 15 ng (lanes 3 and 7), 45 ng (lanes 4 and 8) and 145 ng (lanes 5 and 9) per 30 ul reaction, respectively. Lanes 6-9
5 contained 2 ul of In11 extract containing approximately 3 ng of In11.

Detailed Description of the Invention

5 This invention provides an isolated nucleic acid encoding an integrase interactor 1 gene (ini-1). In one embodiment of this invention, the isolated nucleic acid is DNA encoding the integrase interactor 1 gene that is free of one or more introns present in genomic DNA. In other embodiments of this invention, the isolated nucleic acid sequence described herein are cDNA or
10 genomic DNA. The DNA may be labelled with a detectable moiety selected from a group consisting of a fluorescent label, a radioactive atom, and a chemiluminescent label.

15 In one embodiment of the invention replicable vectors which comprise the nucleic acid described herein are also provided. The replicable vectors include those where the nucleic acid is free of introns. Suitable vectors comprise, but are not limited to, a plasmid or
20 a virus.

The DNA sequence described and claimed herein is useful for the information which it can provide concerning the amino acid sequence of the polypeptide. The sequence
25 is useful for generation new cloning and expression vectors, transforming and transfecting prokaryotic, eucaryotic and bacterial host cells, and new and useful methods for cultured growth of such host cells capable of expression of the polypeptide and related products.

30 The invention further provides a purified polypeptide comprising naturally-occurring ini-1, the polypeptide may be the product of prokaryotic or eukaryotic expression of an exogenous DNA sequence. The exogenous
35 DNA sequence is a cDNA or a genomic DNA sequence. The exogenous DNA sequence may be carried on an autonomously replicating DNA plasmid or viral vectors.

-13-

In one embodiment the purified polypeptide of ini-1 may be human ini-1.

5 The invention also provides for the purified polypeptide possesses part or all the amino acid sequence of human ini-1 as shown in Figure 4 or any naturally occurring allelic variant thereof. The purified polypeptide may have in vivo or in vitro biological activity of naturally occurring ini-1. The
10 purified polypeptide may be covalently associated with a detectable label substance.

The invention also provides a method of determining whether a compound is capable of interfering with the
15 formation of a complex between a retrovirus integrase protein and an ini-1 protein, which comprise the following steps:

- 20 a) incubating the compound with an appropriate ini-1 affinity fusion protein and the retrovirus integrase protein;
- 25 b) contacting the incubate of step (a) with an appropriate affinity medium under conditions so as to bind the ini-1 affinity protein complex, if such a complex forms; and
- 30 c) measuring the amount of the ini-1 affinity protein complex formed in step (b) so as to determine whether the compound is capable of interfering with the formation of the complex between the retrovirus integrase protein and the ini-1 protein.

35 In one preferred embodiment, the retrovirus integrase protein may be HIV-1 IN, the affinity fusion protein may be GST-ini-1. The affinity medium may be

-14-

5 glutathione-agarose beads. The amount of the affinity protein complex formed may be determined using monoclonal or polyclonal antibodies. The above method may also be performed using a retroviral integrase protein fusion.

10 In one preferred embodiment the ini-1 affinity protein complex or the retrovirus integrase affinity protein complex is bound to the affinity medium. The ini-1 affinity protein complex or the retrovirus integrase affinity protein complex is purified and removed from the affinity medium and the amount of integrase protein or ini-1 protein is determined. The amount of the integrase protein or ini-1 protein may be determined using monoclonal or polyclonal antibodies. The above assays may be performed *in vivo* or *in vitro*.

20 The invention also provides for a method of disrupting a retrovirus life cycle in a cell which comprises contacting the cell with a compound which is capable of disrupting a retrovirus integrase protein-ini-1 protein interaction so as to thereby disrupt the retrovirus life cycle. The compound contacting the cell may be a soluble ini-1 fragment, a HIV-1 IN fragment or a chemical molecule. The soluble ini-1 fragment may be a small peptide of 4 to 20 amino acids in length, in one preferred embodiment there may be 6 to 12 amino acids. Other fragments may include non-peptide mimics of ini-1 fragments.

30 A method of disrupting a retrovirus life cycle in a mammal which comprises administering to the mammal a compound which is capable of disrupting a retrovirus integrase protein-ini-1 protein interaction so as to thereby disrupt the retrovirus life cycle. The compound administered to the mammal may be a soluble ini-1 fragment, a HIV-1 IN fragment or a chemical molecule.

-15-

The invention provides an isolated cDNA encoding an integrase interactor 1 gene (ini-1) having a coding sequence substantially the same as the coding sequence as shown in Figure 4.

5

For the above-identified compounds and methods the retrovirus may be selected from the following groups, Avian leukosis sarcoma, Mammalian C-type, B-type viruses, D-type viruses, HTLV-BLV group, Lentiviruses and "Foamy viruses. The retroviruses may also be selected from the following examples, Rous sarcoma virus (RSV), Avian myeloblastosis virus (AMV), Avian erythroblastosis virus (AEV), Rous-associated virus (RAV)-1 to 50, RAV-0, Moloney murine leukemia virus (MO-MLV), Harvey murine sarcoma virus (HA-MSV), Abelson murine leukemia virus (A-MuLV), AKR-MuLV, Feline leukemia virus (FeLV), Simian sarcoma virus, endogenous and exogenous viruses in mammals, Reticuloendotheliosis virus (REV), spleen necrosis virus (SNV), Mouse mammary tumor virus (MMTV), Mason-Pfizer monkey virus (MPMV), "SAIDS" viruses, Human T-cell leukemia (or lymphotropic) virus (HTLV), Bovine leukemia virus (BLV), Human immunodeficiency virus (HIV-1 and -2), Simian immunodeficiency virus (SIV), Feline immunodeficiency virus (FIV), Visna/Maedi virus, Equine infectious anemia virus (EIAV), Caprine arthritis-encephalitis virus (CAEV), Progressive pneumonia virus, many human and primate isolates e.g., simian foamy virus (SFV).

30 This invention is also directed to pharmaceutical compositions comprising therapeutically effective amounts of compounds of the invention together with suitable diluents, preservatives, solubilizers, emulsifiers and adjuvants. Administering a
35 therapeutically effective amount refers to that amount which provides therapeutic effect for a given condition and administration regime. Such compositions are

-16-

liquids or lyophilized or otherwise dried formulations and include diluents of various buffer content (e.g., Tris-HCL, acetate, phosphate), pH and ionic strength, additives such as albumin or gelatin to prevent adsorption to surfaces, detergents (e.g., Tween 20, Tween 80, Pluronic F68, bile acid salts), solubilizing agents (e.g., glycerol, polyethylene glycol), antioxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., Thimerosal, benzyl alcohol, parabens), bulking substances or tonicity modifiers (e.g., lactose, mannitol), complexation with metal ions, or incorporation of the material into or onto particulate preparations of polymeric compounds such as polylactic acid, polyglycolic acid, hydrogels, etc. or into liposomes, microemulsions, micelles, unilamellar or multilamellar vesicles, erythrocyte ghosts, or spheroplasts. Such compositions will influence the physical state, solubility, stability, rate of in vivo release. Controlled or substained release compositions include formulation in lipophilic deposits (e.g., fatty acids, waxes, oils). Also included in this invention are particulate compositions coated with polymers (e.g., poloxamers or poloxamines). Other embodiments of the compositions of the invention incorporate particulate forms protective coatings and permeation enhancers for various routes of administration, including parenteral, pulmonary, nasal and oral.

The following examples are offered to more fully illustrate the invention, but are not to be construed to limit the scope thereof.

-17-

Isolation of cDNAs encoding proteins that interact with HIV-1 IN

To identify human proteins that bind to the HIV-1 integrase, the yeast two hybrid system was used to screen a large library of human cDNAs. In this system, the expression of two constructs in yeast--one encoding the GAL4 DNA binding domain (GAL4DB) fused to one protein, and the other encoding the GAL4 activator domain (GAL4AC) fused to another protein--results in the reconstitution of GAL4 function if the two proteins bind with sufficient affinity (Fields and Song, 1989). The appearance of GAL4 function can be detected by monitoring the expression of an integrated reporter gene, such as lacZ, downstream of a GAL4-dependent promoter. Previously the system was used to detect several interactions between viral and host proteins (Luban et al., 1992; Luban et al., 1993), and in particular to detect IN-IN multimerization (Kalpana and Goff, 1993).

To generate a library of GAL4 activator domain-cDNA fusions, the inserted sequences of a human cDNA library derived from the HL60 macrophage/monocytic cell line were excised from the original phage vector and transferred in bulk to a plasmid vector. Six different pools of plasmids were prepared, each containing 100,000 to 500,000 individual clones (Table 1).

30

Table 1

Library Pools	Number of Original E. Coli. Clones	IN-interacting clones recovered
Pool I	0.23x10 ⁵	-
Pool II	0.5x10 ⁵	One
Pool III	5.00x10 ⁵	-
Pool IV	3.00x10 ⁵	-
Pool V	1.5x10 ⁵	-
Pool VI	1.00x10 ⁵	Two

Table 1 is a summary of recombinant clones in various pools of HL60 cDNA library and positive IN-interacting clones obtained from each pool in the two hybrid screen.

Yeast strain GGY1::171, which contains an integrated reporter gene, was transformed with a mixture of a given DNA pool and an equal amount of pGAL4DB-IN DNA, encoding a fusion protein consisting of the GAL4 DNA binding domain and the entire HIV-1 IN (Kalpana and Goff, 1993). Cotransformants were recovered after selection for markers on both plasmid vectors, and colonies were replicated to filters and stained with X-gal. 10 blue colonies were obtained from a total of 600,000 transformants screened (Table 1). The plasmids were rescued from these colonies and retested by transformation along with the plasmid encoding GAL4DB-IN into GGY1::171. Three of these candidate clones consistently tested positive upon cotransformation: one from pool II and two from pool VI. Subsequent analysis of these clones (see below) showed that all three contained identical cDNA inserts. Thus, a single cDNA was identified in this large-scale screen as encoding a protein able to interact with the HIV-1 IN. The novel gene was termed *ini-1* for integrase interactor 1.

-19-

**Specificity of the interaction between novel sequences
and HIV-1 IN**

Many cDNAs initially isolated as candidates in the two-
hybrid system do not in fact depend on interaction with
5 the partner hybrid protein, but instead activate
expression of the indicator gene through other means
(Luban et al., 1993). To demonstrate a requirement of
the partner for interaction, the GAL4AC-ini-1 fusions
were tested for activation in several settings (Table 2).

10

Table 2

Fusion Proteins	Promoter	Operator	β -gal Activity
GAL4DB-IN + GAL4AC-INI	GAL1	UAS _G	++++
GAL4DB-IN + GAL4AC-INI	GAL1	UAS _G	++++
GAL4DB-MG + GAL4AC-INI	GAL1	UAS _G	-
GAL4DB + GAL4AC-INI	GAL1	UAS _G	-
GAL4AC-INI	GAL1	UAS _G	-
LexADB-IN + GAL4AC-IN	GAL1	LexA	++++
LexADB-IN + GAL4AC-INI	GAL1	LexA	++++
LexADB-lamin + GAL4AC-INI	GAL1	LexA	-
LexADB + GAL4AC-INI	GAL1	LexA	-
GAL4AC-INI	GAL1	LexA	-

Table 2 shows the specificity of IN-ini-1 interaction in yeast under various conditions of promoters and DNA binding domains. Two plasmids, one encoding GAL4DB fusion and the other encoding GAL4AC fusions were co-transformed into either GGY1::171 (for testing the GAL4DB fusions) or CTY10-5d (for testing LexADB fusions). The transformants were scored for b-gal activity. Fusion protein GAL4DB-IN was encoded by plasmid pMAL, GAL4AC-IN by pGADI, GAL4AC-INI by pD2.1, LexADB by pSH2-1, LexADB-IN by pSHIN, and LexADB-lamin by pLexAlamin.

-21-

Transformation of GGY1::171 by the GAL4AC-ini-1 plasmids alone, without pGAL4DB-IN, did not activate *lacZ* expression. Cotransformation with a plasmid encoding GAL4DB alone also did not activate, suggesting that the ini-1 protein did not interact directly with the GAL4 DNA binding domain. To confirm that the activation was not restricted to the GAL4 system, the DNAs were introduced into strain CTY10-5d, containing an integrated *GAL1-lacZ* fusion downstream of the *lexA* operator, along with a plasmid encoding a LexA-IN fusion, or as control, LexA alone. *LacZ* expression was detected only when the GAL4AC-ini-1 protein was present with LexA-IN fusions and not with the LexA protein alone. These results indicate that activation by ini-1 fusions was not dependent on the particular operator and binding domain used to tether the IN protein to DNA.

To determine whether the ini-1 protein could interact with unrelated fusion proteins, the three ini-1 plasmids were introduced into the appropriate indicator strain along with control plasmids encoding a GL4DB-Moloney gag fusion or a *lexA*-Lamin fusion protein. No *lacZ* expression was detected in either of these settings, indicating that activation by the cDNA fusions was specific for the HIV-1 IN protein (Table 1). Thus, in contrast to other screens for interacting partners with other proteins, where many RNA-binding proteins were initially detected, there were no false positive clones recovered with IN. The results suggest that the original GAL4-IN construct was not prone to interaction with false positives, but bound uniquely to a human protein encoded by a single cDNA.

The central domain of IN is required for interaction with ini-1

The two hybrid system has been previously used to

-22-

define the minimal region of IN required for IN-IN interactions, finding that the central core region of the protein was necessary for multimerization (Kalpana and Goff, 1993). To determine the region of IN required for binding to ini-1, a panel of mutants of pGAL4DB-IN were tested containing deletions and point mutations for activation in the presence of GAL4AC-ini-1. Mutants lacking either the N-terminal domain of IN, containing a putative zinc finger region, or the C-terminal domain, retained their ability to bind to ini-1 (Figure 1). Two larger C-terminal deletions, removing part of the central core and eliminating IN-IN interactions, did not affect In-ini-1 interaction. In addition, a variant containing a point mutation in the C-terminal region of IN that blocked IN-IN interaction (Kalpana and Goff, unpublished date) was still positive for IN-ini-1 interaction. Thus, the IN-ini-1 interaction requires less of the IN central and C-terminal domains than the IN-IN interaction. Two mutants of IN with point mutations in the N-terminal zinc finger region were also tested. While these mutants still carry out IN-IN interactions, they were both defective for the In-ini-1 interaction. Thus, binding to ini-1 seems to require the N-terminal zinc finger region of IN. While the two interaction domains--that for IN-IN dimerization and that for In-ini-1 interaction--may overlap, the IN-ini-1 domain seems to be more N-terminal.

30 Expression of the ini-1 mRNA in mammalian cells

The cDNA inserts recovered in the GAL4AC plasmids were derived from mRNAs of the HL60 human monocytic-myelocytic cell line, suggesting that the gene must be expressed in at least moderate levels in this tumor line. The sequences present in the cDNA insert might include only a portion of the complete mRNA. To

-23-

determine how widely the *ini-1* mRNA was expressed, and to determine the size of the full-length transcript, RNAs were isolated from HeLa cells, a human B-cell tumor line (CB33), and a human T-cell line (Hut78), and analyzed by Northern blot hybridization using an *ini-1* probe (Figure 2). RNAs from all three lines contained a single major species detected with the probe, migrating at approximately 2.0 kb. In addition, the HeLa and CB33 lines contained a minor species migrating at approximately 4.0 kb. To determine whether the *ini-1* gene was expressed in normal tissues, RNAs isolated from peripheral blood lymphocytes, colon, small intestine, ovary, testis, prostate, thymus and spleen were separated by electrophoresis, blotted and probed as before (Figure 2). All 8 tissues expressed substantial levels of the 2.0 kb mRNA. The level of expression of the mRNA was similar in all the tissues tested. In addition to the major mRNA species, long exposures of the autoradiographs revealed low levels of a species migrating at 1.25 kb present in the spleen, and similarly low levels of a species migrating at about 4 kb in the thymus, prostate and testes. These results suggest that the *ini-1* gene is very widely, and possibly ubiquitously, expressed, and that the major transcript in all tissues is approximately 2.0 kb in length. Additional transcripts with alternative structures, or transcripts from closely related genes, may be present in some tissues.

Isolation of cDNAs spanning the complete *ini-1* coding region and predicted sequence of the *ini-1* protein

The cDNA inserts in the three GAL4AC plasmids recovered were examined by restriction mapping and partial sequence analysis, and all were found to consist of the identical 1.0 kb fragment, presumably from sibling clones in the original phage library. To isolate longer cDNAs, this fragment was excised from the

plasmid and used as a probe to screen two phage cDNA libraries of HeLa cell mRNA, one made in the λ ZapII vector and one in λ gt11. 20 clones were recovered from approximately 600,000 clones of the λ ZapII library, and the six largest inserts were excised from the vector. Four of these had overlapping restriction maps (Figure 3) consistent with that of the probe DNA and were subjected to sequence analysis. 12 clones were recovered from the λ gt11 library but no inserts were larger than the earlier clones; one of these cDNAs was also sequenced. The DNA sequences obtained could be readily aligned, and spanned 1.85 kb, nearly the size of the full-length mRNA detected by Northern blots (Figure 3).

The DNA sequence from the clones contained several unusual features (Figure 4; SEQ ID NO:1). First, the sequence was extraordinarily GC-rich and included several long stretches of pure GC runs. These features made determination of the sequence by dideoxynucleotide methods difficult, and several regions could only be read from smaller subclones that presumably removed secondary structures from the DNA templates. The sequence revealed a single long open reading frame of 385 codons, curiously beginning with a tandem array of four consecutive ATG codons. The first ATG of the array lies in a good match to the consensus sequence for translational initiation (Kozak, 1991). These codons are likely to represent the true start sites for translation, since termination codons are found upstream of these ATGs. The significance of the presence of these tandem methionine codons remains unclear. The one clone from the λ gt11 library (pINI.gt) contained a stretch of poly(A) residues at the 3' junction adjacent to the vector, and three of the clones from the λ ZAPII library had 3' junctions at or upstream of this position, such that they could have

-25-

been derived from a similar mRNA. Examination of the sequence upstream of the poly(A) stretch revealed the presence of a perfect consensus polyadenylation signal, AATAAA, at -25 bp relative to the poly(A). These results suggest that most of the *ini-1* mRNAs are processed by cleavage and polyadenylation at this position. One cDNA clone (pINI.21), however, extended beyond this region without poly(A) sequences. This clone suggests that some mRNAs are of extended length and arise through use of alternative poly(A) addition sites further downstream. These RNAs could possibly account for the longer mRNAs observed in Northern blots of mRNAs from various tissues. One clone, (pINI.9), lacked a short stretch of 27 bp (nt 206-232) near the 5' end of the coding region. This clone might have arisen from an alternatively spliced mRNA lacking an internal exon.

The long open reading frame predicts the formation of a protein of 44,131 daltons containing 385 amino acids. The sequence revealed the presence of a heptad repeat of three leucine residues near the amino-terminus of the encoded protein; these residues could potentially form a leucine zipper structure. While these sequences might be important for multimimerization, interactions with other proteins, or for the normal function of the *ini-1*, these structures can be eliminated as important for interaction with the IN protein since they are not present in the original yeast plasmid clone that demonstrated binding to IN. The predicted sequence includes no amino-terminal secretion signals, no transmembrane segment, and no strikingly acidic or basic regions. There are three potential sites for addition of N-linked sugars (Figure 4). The predicted pI of the protein is 6.15.

-26-

ini-1 has sequence similarity to SNF5

Comparison of the predicted sequence of ini-1 with the known sequences in the GenEmbl data base revealed a single significant match, the SNF5 protein of *S. cerevisiae*, encoding a transcriptional activator protein (Abrams et al., 1986; Laurent et al., 1990; Neigeborn and Carlson, 1984). SNF5 is a nuclear protein thought to act in a complex with several other proteins including SNF2/SWI2, SNF6, SWI1, and SWI3, to activate target gene expression (Laurent et al., 1991; Peterson and Herskowitz, 1992). The alignment of ini-1 with the SNF5 sequence displayed three regions of close similarity, with 33-55% sequence identity and 41-71% of conserved residues (Figure 5A and 5B; SEQ ID NO:3-4). All three regions lay in the central portion of the SNF5 sequence rich in charged amino acids and the flanking N- and C-terminal portions of the yeast gene were not conserved in the human gene. In particular, the proline- and glutamine-rich segments of the yeast protein were not retained. Based on the striking similarity between the yeast and human genes in the core coding region, the ini-1 may be a human homologue of the yeast SNF5 gene.

IN binds to ini-1 in vitro

To demonstrate that ini-1 interacts directly with IN in solution, binding studies between recombinant proteins were carried out in vitro. The ini-1 cDNA from plasmid pD2.1 was inserted into plasmid pGEX and expressed as a glutathione S-transferase fusion protein in *E. coli*. Lysates of the bacteria were prepared, and the GST-ini-1 protein was affinity purified on glutathione agarose beads (G-beads). The beads were washed extensively to remove nonspecific proteins. To ensure that the GST-ini-1 proteins were successfully expressed and bound to the beads, the proteins on the beads were recovered by boiling in SDS, and examined by SDS-PAGE (Figure 6A).

-27-

A novel protein of the expected size (60 kd) was recovered from lysates containing the GST-ini-1 protein, and represented 70-80% of the total protein.

- 5 The immobilized ini-1 was used as an affinity matrix for binding of IN. The HIV-1 IN protein was expressed in *E. coli* from the T7 promoter after induction of the T7 polymerase, and soluble IN protein was extracted from inclusion bodies with buffer containing high salt.
- 10 These lysates were then incubated with G-beads alone, G-beads with GST alone, or G-beads with GST-ini-1, the beads were washed extensively, and the bound proteins were recovered with SDS. The eluted proteins were separated by SDS-PAGE, blotted to nitrocellulose, and
- 15 visualized with polyclonal antibodies specific for HIV-1 IN (Figure 6B). The results showed that the recombinant IN bound efficiently to the ini-1 beads and not to the control GST beads or the beads alone.
- 20 To further characterize the IN-ini-1 interaction, binding experiments were repeated under various conditions (Figures 6B and 6C). Binding was observed over a wide range of salt concentrations, and was detected even in the presence of 1 M NaCl. The IN was
- 25 retained by the ini-1 beads when washed with buffers containing 0.5% NP40 or 0.1% Triton X-100. The interaction was disrupted, however, by the addition of 0.1% SDS, suggesting that denatured IN and ini-1 proteins could not bind.
- 30 ini-1 acts as a transcriptional activator in yeast when expressed as a DNA binding domain fusion protein. The yeast SNF5 protein is a transcriptional activator, required for the high-level of expression of many genes
- 35 in yeast. Though the protein has not been shown to bind to DNA directly, it is capable of activating a reporter gene when artificially tethered to DNA by

-28-

fusion to the lexA DNA binding domain (Laurent et al., 1990). To determine whether ini-1 could also act as a transcriptional activator in this setting, a construct encoding a fusion of GAL4 DNA binding domain-ini-1 was generated and expressed in an indicator strain containing a GAL1-lacZ reporter. The transformants expressed high levels of β -galactosidase as judged by staining with x-gal, while control transformants expressing only the GAL4DB or GAL4AC-ini-1 protein did not. Thus, like SNF5, the human ini-1 protein can activate transcription in yeast.

The ini-1-IN interaction

The two-hybrid system has been used to seek human proteins that might be involved in retroviral replication. The novel gene identified in this screen, ini-1, encodes a protein which is capable of binding the HIV-1 IN both in vivo and in vitro. The fact that all three clones recovered in the screen were identical, and that no other clones were identified in a large number tested, suggests that ini-1 is the major human protein capable of binding to IN. It is noteworthy that there were no false positive clones at all detected in this screen, suggesting that the GAL4DB-IN fusion used here did not allow interactions to the GAL5 region or other proteins that often produce false positives. The binding seemed to be very specific, and could be observed in the setting of several fusion constructs including either the GAL4 or LexA binding domains. The interaction measured in vitro was tight and was resistant to high salt, suggesting that it may involve hydrophobic contacts on the two partners. The binding in solution was also specific, with no significant binding of IN to GST or GST-cyclophilin proteins (Luban et al., 1993) tested as controls.

-29-

The region of IN required for binding to ini-1 was a portion of the central domain; the very N- and C-terminal regions were dispensable. The essential region for interaction to ini-1 was distinct from that for multimerization of IN, apparently lying more toward the N-terminus of the protein. Mutants of IN that showed differential effects on the two interactions were readily obtained. It is possible that the ini-1 protein can bind to a multimer of IN and stabilize multimer formation, or it could block or compete for IN multimerization. ini-1 could stimulate concerted joining of both termini into target DNAs, accelerating functional integration reactions; or, alternatively, it could inhibit concerted joining of two termini of the viral DNA to the target sequence, acting to restrain normal retroviral integration. The function of ini-1 can be explored through analysis of its effects on various *in vitro* integration activities.

20 Targeting retroviral integrations

The presence of a protein like ini-1 in an infected cell able to bind the HIV-1 IN could be responsible for targeting proviral insertion to selected sites in the genome. The phenomenon of non-random integration of retroviral and retrotransposon DNAs is well-established, but the mechanisms by which targeting occurs remain uncertain. Insertions seem to preferentially occur into transcriptionally active regions, and perhaps into open chromatin (Rohdewohld et al., 1987; Vijaya et al., 1986). In the case of the yeast transposon Ty3, site selection is profoundly specific, with insertions almost always occurring at a position 16 or 17 bp from the site of initiation of polIII transcripts (Chalker and Sandmeyer, 1990; Chalker and Sandmeyer, 1992). Analysis of mutant promoter sequences and of hybrid target sites strongly suggest that nuclear protein complexes including

-30-

TFIIIA, TFIIIB, and TFIIID are responsible for site selection, and for precise positioning of the insertion into the promoter (Sandmeyer et al., 1990). In the case of the transposon Ty1, site selection is more relaxed, but analysis of a large number of insertions into yeast chromosome III suggests that insertions tend to occur within regions clustered within 400 bp of polIII genes (Ji et al., 1993). Such preferences might be mediated by the accessibility of stretches of DNA, or by interactions of the transposon-IN complex with chromatin of other DNA-bound proteins. The existence of a mammalian protein with high affinity for the HIV-1 IN is consistent with its playing a similar role in site selection for retroviral insertion.

Function of the ini-1 protein: reorganization of chromatin structure

SNF5 is a transcriptional activator in yeast, and is required for transcription of many unrelated genes such as *SUC2*, *HO*, *INO1*, *PHO5*, and *GAL1*, 7 and 10. In addition, it is required for the function of many gene-specific activators, including *GAL4*, *Bicoid*, and the glucocorticoid receptor (Laurent and Carlson, 1992; Yoshinaga et al., 1992). Genetic experiments suggest that the yeast SNF5 protein acts in a enormous complex with the products of the *SWI1*, *SNF2/SWI2*, *SWI3*, *SNF6*, and possibly other genes (Laurent et al., 1991; Peterson and Herskowitz, 1992), and co-immunoprecipitation studies using antibodies to yeast SNF5 confirm its presence in a large complex. The SNF2 subunit of the complex has domains similar in sequence to DNA helicases (Davis et al., 1992; Laurent et al., 1992), and has been shown to exhibit DNA-dependent ATPase activity (Laurent et al., 1993). Mammalian homologues of the yeast SNF2/SWI2 products have recently been identified (Khavari et al., 1993;

Muchardt and Yaniv, 1993; Okabe et al., 1992)

5 The SNF and SWI transcription factors may act by helping to reorganize chromatin structure (for review, see Winston and Carlson, 1992). Deletions of one copy of the genes encoding histones H2A and H2B can suppress the defects in Ty and SUC2 transcription caused by *snf2*, and 5 mutations (Clark-Adams et al., 1988; Happel et al., 1991), and these suppressors probably act by
10 inducing changes in the chromatin structure as assayed by microccal nuclease digestion experiments (Hirschhorn et al., 1992). Other suppressors of *snf* and *swi* mutations have been identified as alleles of a gene encoding histone H3 (cited in Peterson and Herskowitz, 15 1992), and of a gene encoding a nonhistone DNA binding protein similar to HMG1 (Kruger and Herskowitz, 1991). These observations suggest that the normal role of the SNF and SWI genes may be to alter the arrangement of nucleosomes on target genes to facilitate their
20 transcription. The unexpected sequence similarity of the *ini-1* protein to SNF5 is intriguing: the similarity implies that *ini-1* may be a novel transcriptional activator in human cells, and may act in a complex to decondense chromatin. The ability of the human
25 sequence to activate a reporter gene in yeast when tethered to DNA lends further support to this notion. Such a role is also consistent with its affinity for HIV-1 IN, and would suggest that *ini-1* might indeed account for the propensity of retroviral DNA to insert
30 into active genes.

Finally, the identification of a host protein as
interacting with the HIV-1 IN raises the possibility that it may be used as a novel route to inhibit viral
35 replication. If the protein serves to stimulate integration, then drugs which could block the *ini-1*-IN interaction might retard viral spread. In addition, it

might be possible to generate dominant negative alleles of *ini-1*, perhaps encoding small fragments of the protein, that bind inappropriately to IN and block its activity.

5

The retroviral integrase protein (IN) is responsible for the insertion of the viral DNA into host chromosomal targets. The two hybrid system has been used to screen a human cDNA library expressed as GAL4 fusion proteins in yeast for gene products that interact with the human immunodeficiency virus type 1 IN. The screen led to the recovery of three independent isolates of the same gene from approximately 10^6 colonies. The protein encoded by this gene bound tightly to the HIV-1 integrase *in vitro*. The sequence of the gene suggests that the novel protein is a human homologue of yeast SNF5, a transcriptional activator required for high level expression of many genes. The new gene is termed *ini-1* for integrase interactor 1, encodes a nuclear receptor for incoming viral integration complexes, and may be a component of the long-sought mechanism for biased target site selection during provirus integration.

25

Bacterial and yeast strains: Yeast strain GGY1::171 (MAT α leu2-3,112 his3-200 met-tyr1 ura3-52 ade2 gal4 Δ gal80 Δ URA3::GAL1-lacZ) (Fields and Song, 1989) contains an integrated GAL1-lacZ reporter gene; CTY 10-5d (MATa ade2 trp1-901 leu2-3, 112 his3-200 gal80-URA3::LexA-LacZ) contains an integrated GAL1-lacZ gene with *lexA* operator. β -galactosidase assays, both in liquid cultures and on nitrocellulose lifts, were carried out as published with minor modifications (Chien et al., 1991). *E. coli* strains DH5 α (BRL), XL1blue and SURE (Stratagene) were used for subcloning plasmids; strain BL21(DE3) was used for the expression of recombinant proteins from T7 promoters.

30

35

Construction of various recombinant plasmids:

Construction of plasmids pMAI (encoding GAL4DB-IN fusion), and PGADI (encoding GAL4AC-IN), pSHIN (LexADB-IN fusion) and pMA-MG (encoding the GAL4DB fused to the Moloney MuLV Gag protein) have been previously described (Kalpana and Goff, 1993; Luban et al., 1992). Plasmids pGVK10 (expressing the GST-ini-1 fusion protein) and pMAI (expressing GAL4DB-ini-1) were constructed by transfer of the EcoRI cDNA fragment of the interacting clone pD2.1 to the unique EcoRI sites of pGEX-1 λ T and pMA424, respectively. Construction of IN mutants pMAHH, pMACC, pMAAN3, pMAAC2 and pMAAC3 were described earlier (Kalpana and Goff, 1993). The remaining IN deletion mutants, pMA Δ 18 to pMA Δ 273, were originally isolated as GAL4AC fusion mutants that retained the ability to interact with GAL4DB-IN. The BamHI-SalI fragments from these mutants were excised from the GAL4AC plasmid and transferred into pMA424. Isolation of pMAM5, encoding a mutant IN defective for IN-IN interaction, will be described elsewhere.

Construction of HL60 cDNA library fused to the activation domain of GAL4:

The HL60 cell cDNAs were excised from a λ Zap HL60 cDNA library (Stratagene catalogue # 936214). The original λ Zap library encompassed about a million recombinant phage clones. To ensure that complexity of the original library was retained, a plate lysate of the phage library was prepared by plating 10^7 phage; phage particles were isolated by PEG precipitation and two consecutive steps of CsCl gradient centrifugation. DNA was isolated from the total phage by standard methods. About 100 μ g of DNA was digested with NotI and XhoI, separated on agarose gels and inserts 0.2- 3.0 kb in size were isolated by electroelution. The cDNA inserts were ligated to the pGADNot vector (Luban et al, 1993)

-34-

5 digested with NotI plus SalI and phosphatase-treated. DH5 α cells were transformed with the ligation products and the transformants from six individual batches of 100,000 to 500,000 colonies each were pooled separately in LB/Amp (KGLI, pool I to Pool VI). This unamplified library in pGADNot vector was aliquoted into small vials and stored frozen until further use. The ratio of non-recombinants to recombinants in the library was determined by comparing the number of transformants obtained with self ligated vector to that obtained with vector ligated to insert; and by examining plasmids from several individual colonies to determine the presence of insert. Both these tests indicated that there were >95% recombinants in the library. The plasmid library DNA was isolated from 1 l cultures of each pool by Quiagen columns. This DNA was used for transformation into yeast strain GGY1::171.

20 Transformation of yeast and screening for interacting clones

Overnight cultures of GGY1::171 were diluted 1:50 or 1:100 in YPAD (YEPD supplemented with 30 μ g/ml of adenine) and incubated at 30°C until the OD₆₀₀ reached 0.25-0.4. The cells were pelleted, washed once with 1/10th volume of 100 mM LiAc/10 mM TE, and resuspended in 1/200th volume of the same buffer. The cells were further incubated with shaking for 1 hour at 30°C. The competent cells were incubated with 1-10 μ g of plasmid DNAs encoding GAL4DB and GAL4AC fusions, 20 μ g of sonicated salmon sperm carrier DNA (Sigma, catalogue # D-9156) and 40% PEG in LiAc/TE with agitation at 30°C for 30 minutes. After the PEG treatment, the cells were pelleted and resuspended in 1 ml of YPAD and incubated further for 1 hour at 30°. The post-incubation step increased the efficiency of co-transformation by about 10 fold. Cells were pelleted, resuspended in TE and plated on selective medium.

-35-

In vitro binding of GST-ini-1 fusion protein to HIV-1 IN

Bacterial extracts containing GST-ini-1 fusion protein were prepared as follows. Overnight bacterial cultures containing the required plasmid was diluted 1:10 into LB/Amp and incubate at 37°C until the O.D.₆₀₀ was ~0.5. IPTG (isopropyl- β -D-thiogalactopyranoside) was added to a final concentration of 1 mM and incubation was continued for 3-5 hours. The cells were collected and resuspended in buffer Y (50 mM Tris/Cl pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.5% NP-40 and 1 mM PMSF). Lysozyme was added to a final concentration of 1 mg/ml and incubation was continued on ice for half an hour. This lysate was subjected to sonication (3 x 30 sec bursts). The lysate was clarified in a microfuge for 15 minutes, and the supernatant was transferred to a fresh microfuge tube. Pre-swollen G-beads were added to the above lysate and incubated at 4°C for 30 minutes with gentle rocking. The beads were spun at 1600 RPM in the microfuge for 20 sec and the resulting pellet was washed three times with excess of buffer Y and resuspended in buffer Y to yield a 50% (v/v) slurry.

Bacterial extract containing HIV-1 IN was prepared as follows. Overnight bacterial cultures of BL21(DE3) containing either one of the plasmids, pT7f11-IN (encodes IN under the control of T7 promoter), and pT7- Δ IN (control plasmid from which IN is deleted) were diluted 1:10 in LB/Amp and incubated at 37°C for 1 hour. IPTG was added to a concentration of 1mM and incubation was continued for 3-5 hours. The cultures were pelleted and the pellets were resuspended in buffer Y. Lysozyme was added to a final concentration of 1 mg/ml and the cells were incubated on ice for 30 minutes. The lysed bacteria were sonicated and passed through a syringe with a 23 Gauge needle several times. The insoluble material was collected by centrifugation

-36-

and resuspended in buffer containing 1 M NaCl and 1 mM DTT, and the mixture was subjected to gentle rocking at 4°C for 30 minutes. The resulting solution was spun in the microfuge for 30 minutes and the supernatant, referred to as 1M NaCl extract of IN, was used for the binding assay with GST-ini-1.

The binding of IN to GST-ini-1 was tested by adding the washed G-beads with bound GST-ini-1 to the 1M NaCl extract of IN and incubating for 30 minutes at 4°C in buffer containing 1 M Hepes, pH 7.3, 200 mM NaCl, 5 mM DTT, 0.1% NP-40, 1 mM PMSF and 10 mg/ml BSA. To test the effect of salt, the concentration of NaCl was varied in the binding buffer from 200 mM to 1 M. The mixture was incubated at 4°C for 30 minutes and washed three times with excess of either buffer Y or buffer Y containing various concentrations of NP-40 and SDS. The resulting beads were boiled in Laemmli buffer and subjected to SDS-PAGE in duplicate. The presence or absence of IN in these binding experiments was determined by Western analysis using monoclonal antisera to IN.

Screening the phage library to isolate full length recombinant clones of ini-1

Two HeLa cDNA libraries, one constructed in λ Zap II vector (Stratagene, Cat. #936201) and one constructed in λ gt11, were screened using standard methods. The cDNA insert from one positive interacting clone obtained in the yeast screen was purified, labelled by random priming with 32 P-dCTP, and used as a probe to screen about 0.5×10^6 phage of the λ ZapII library. DNA isolated from twenty positive clones obtained after three rounds of plaque purification was subjected to restriction analysis. Six positive clones that had the largest inserts were chosen for further analysis. The recombinant pBluescript phagemids from these six

-37-

positive λ ZapII clones were subjected to *in vivo* excision using the M13 helper phage (Exassist/SOLR system, Stratagene, Cat #200253).

5 **mRNA analyses**

Unfractionated mRNA prepared from HeLa, CB33 and Hut78 cell lines were subjected to Northern analysis using standard methods. A northern Blot of human mRNAs from multiple tissues (Clontech, Palo Alto CA; catalog #7759-1) was hybridized to a labelled *ini-1* probe using standard methods (Maniatis et al., 1982).

10 **Determination of whether In1 protein could affect IN Function:**

15 The enzymatic activities of IN in the presence of increasing concentrations of GST-Ini1F (full length In1) fusion protein was assayed. A full length cDNA clone missing only the first 5 codons was inserted into
20 pGEX2TK and the full length In1 fusion protein (GST-Ini1F) was isolated using G-beads and eluted with 20 mM glutathione. The protein was dialyzed against a large volume of storage buffer (25 mM Hepes, pH 7.2, 50 mM NaCl, 0.1 mM EDTA, 1 mM DTT, 20% glycerol, 1 mM PMSF,
25 1 ug/ml each of pepstatin, aprotinin and leupeptin) and stored at -70°C. Recombinant HIV-1 IN protein was isolated from bacterial cultures carrying plasmid pINC6H essentially as described (Drelich et al. 1992) with minor modifications. Integrase joining activity
30 assays were performed in a total volume of 30 ul, and contained 1 ng of a double-stranded DNA oligonucleotide from the HIV-1 U5 terminus, consisting of one strand labelled at the 5' end, representing the already-processed substrate (sequence 5'-GGATCCGGAAATCTCTAGCA-
35 3'), and its unlabelled complement with extra CA dinucleotide overhang at the 5' end; 10 ng of pBluescript DNA as target; and ~15 ng of IN. The

-38-

5 reactions were stopped by addition of EDTA to 50 mM final concentration. The products were treated with proteinase K and SDS, and analyzed by electrophoresis on a 1% agarose gel. The gel was dried and exposed to autoradiography to monitor transfer of the oligonucleotide to the relaxed circular and linear target DNA.

10 To assay IN DNA joining activity, recombinant IN protein was incubated with ³²P-labeled double-stranded DNA oligonucleotides corresponding to the U5 terminus of the HIV-1 viral DNA as substrate, and with unlabeled plasmid DNA as target. Aliquots of the reaction mixture were removed at various times and analyzed by
15 agarose gel electrophoresis and autoradiography; radioactivity migrating with the relaxed plasmid DNA represented integration of the labeled oligonucleotide into the target. The addition of increasing levels of GST-Ini1F resulted in a strong and dose-dependent stimulation of joining activity (Fig. 8A). Control
20 experiments with GST showed no such stimulation. In some experiments, addition of very high levels of GST-Ini1F resulted in inhibition.

25 To determine whether the native form of Ini1 as present in mammalian cells behaved similarly, nuclear extracts were prepared and the SNF/SWI complex (Ini1 extract) was partially purified. The presence of Ini1 was monitored by Western analysis with polyclonal antisera
30 raised against GST-Ini1. Ini1 cofractionated with Brg1 and the complex through five different conventional columns, and was also retained on Brg1 immunoaffinity columns. The addition of increasing amounts of this preparation to the joining reactions resulted in potent
35 stimulation of IN activity (Fig. 8B). Partial depletion of Ini1 by passage through a Brg1 affinity column resulted in the removal of most of the

-39-

stimulatory activity (Fig. 8B). The amount of stimulation by the extract was constant over a wide range of target DNA concentrations (Fig. 8C). Maximal stimulation of IN activity (10-20 fold) occurred when the IN-Ini1 molar ratio in the reaction mixture was roughly 5:1. Higher concentrations of Ini1 resulted in no further stimulation but rather slight inhibition. Maximal stimulation by native Ini1 required lower concentrations than with the recombinant IN. Stimulation by Ini1 was strongly dependent on the Ini1:IN ratio, with strongest stimulation at low IN concentrations, no stimulation at intermediate concentrations, and inhibition at high IN concentrations (Fig. 8D).

A novel host protein, Ini1, can bind the HIV-1 IN protein and stimulate its DNA joining activity. The protein shows unexpected sequence similarity to the SNF5 protein of yeast (Laurent et al., 1990) which is required for the high-level transcription of many genes, and for the proper functioning of several gene-specific activators (Laurent et al., 1991; Laurent et al., 1992; Yoshinaga et al., 1992; Peterson et al., 1992; and Carlson et al. 1994). Genetic and biochemical experiments suggest that SNF5 is part of a very large complex of proteins able to promote transcription both in vitro and in vivo (Laurent et al., 1991; Laurent et al., 1992; Yoshinaga et al., 1992; Peterson et al., 1992; Carlson et al. 1994; Cairns et al., 1994; and Peterson et al., 1994). The complex may help reorganize chromatin structure. Mutations in *snf2* and *snf5* are suppressed by mutations affecting histones H2A, H2B, and H3, as well as a nonhistone DNA binding protein similar to HMG1, and direct biochemical analysis suggests that the complex can alter nuclease sensitivity of chromatin (Hirschhorn et al., 1992; Kruger et al., 1991; and Winston et al.

(1992). The complex has been shown to alter chromatin structure and promote binding of sequence-specific DNA binding proteins (Kwon et al., 1994; and Imblazano et al., 1994). In11 is retained on an affinity column containing anti-BRG1 antibodies, suggesting that it is in a complex with BRG1. The sequence similarity, the ability of In11 to activate a reporter gene when tethered to DNA, and its presence in the mammalian SWI/SNF complex--strongly suggest that In11 is a functional homolog of the yeast *SNF5* gene.

The affinity of In11 for the HIV-1 IN might account for the propensity of retroviral DNAs to insert into active genes and their associated open chromatin (Vijaya et al., (1986); Rohdewohld et al., (1987); Scherдин et al., (1990); Shih et al., (1988); Withers-Ward et al., (1994)). Upon binding to In11, the preintegration complex could be stimulated to insert the viral DNA into nearby sites. In11 may provide a novel target for antiviral therapy: virus replication might be blocked by drugs that inhibit the IN-In11 interaction or by dominant negative alleles of IN11 that bind inappropriately to IN and block its activity.

References

- 5 Abrams, E., Neigeborn, L., and Carlson, M. (1986).
Molecular analysis of SNF2 and SNF5, genes required for
expression of glucose-repressible genes in *S.*
cerevisiae. *Mol. Cell. Biol.* 6, 3643-3651.
- 10 Bushman, F.D., and Craigie, R. (1991). Activities of
human immunodeficiency virus (HIV) integration protein
in vitro: specific cleavage and integration of HIV
DNA. *Proc. Natl. Acad. Sci. USA* 88, 1339-1343.
- 15 Bushman, F.D., Fujiwara, T., and Craigie, R. (1990).
Retroviral DNA integration directed by HIV integration
protein in vitro. *Science* 249, 1555-1558.
- 20 Cairns, B.R., Kim, Y.-J., Sayne, M.H., Laurent, B.C.,
Kornberg, R.D., *Proc. Natl. Acad. Sci. USA* 91, 1950
(1994).
- Carlson, M., Laurent, B.C., *Current Opinion in Cell*
Biol. 6, 396 (1994)
- 25 Chalker, D.L., and Sandmeyer, S.B. (1990). Transfer
RNA genes are genomic targets for de novo transposition
of the yeast retrotransposon Ty3. *Genetics* 126, 837-
850.
- 30 Chalker, D.L., and Sandmeyer, S.B. (1992). Ty3
integrates within the region of RNA polymerase III
transcription initiation. *Genes Dev.* 6, 117-128.
- 35 Chien, C.-T., Bartel, P.L., Sternglanz, R., and Fields,
S. (1991). The two hybrid system: A method to
identify and clone genes for proteins that interact
with a protein of interest. *Proc. Natl. Acad. Sci. USA*
88, 9578-9582.

- Clark-Adams, C.D., Norris, D., Osley, M.A., Fassler, J.S., and Winstron, F. (1988). Changes in histone gene dosage alter transcription in yeast. *Genes Dev.* 2, 150-159.
- 5 Cote, J., Quinn, J., Worknan, J.L., Peterson, C.L., *Science* 265, 53 (1994).
- 10 Craigie, R., Fujiwara, T., and Bushman, F. (1990). The IN protein of Moloney murine leukemia virus processes the viral DNA ends and accomplishes their integration in vitro. *Cell* 62, 829-837.
- 15 Davis, J.L., Kunisawa, R., and Thorner, J. (1992). A presumptive helicase (MOT1 gene product) affects gene expression and is required for viability in the yeast *Saccharomyces cerevisiae*. *Mol. Cell. Biol.* 12, 1879-1892.
- 20 Dhar, R., McClements, W., Enquist, L., and Vande Woude, G. (1980). Nucleotide sequences of integrated Moloney sarcoma provirus long terminal repeats and their host and viral junctions. *Proc. Natl. Acad. Sci. USA* 77, 3937-3941.
- 25 Drelich, M., Wilhelm, R., Mous. J., *Virology* 188, 459 (1992).
- 30 Farnet, C.M., and Haseltine, W.A. (1991). Determination of viral proteins present in the human immunodeficiency virus type 1 preintegration complex. *J. Virol.* 65, 1910-1915.
- 35 Fields, S., and Song, O.-K. (1989). A novel genetic system to detect protein-protein interaction. *Nature* 340, 245-246.

-43-

Fields, S., and Song, O.-K. (1994). System To Detect Protein-Protein Interactions. U.S. Patent No. 5,283,173.

5 Fujiwara, T., and Mizuuchi, K. (1988). Retroviral DAN integration: structure of an integration intermediate. Cell 54, 497-504.

10 Goff, S.P. (1992). Genetics of retroviral integration. Annu. Rev. Genet. 26, 527-544.

Gorski et. al. Cell 47, 7067 (1986)

15 Happel, A.M., Swanson, M.S., and Winston, F. (1991). The SNF2, SNF5, and SNF6 genes are required for Ty transcription in *Saccharomyces cerevisiae*. Genetics 128, 69-77.

20 Hirschhorn, J.N., Brown, S.A., Clark, C.D., and Winston, F. (1992). Evidence that SNF2/SWI2 and SNF5 activate transcription in yeast by altering chromatin structure. Genes Dev. 6, 2288-2298.

25 Hughes, S.H., Shank, P.R., Spector, D.H., Kung, H.-J., Bishop, J.M., Varmus, H.E., Vogt, P.K., and Breitman, M.L. (1978). Proviruses of avian sarcoma virus are terminally redundant, co-extensive with unintegrated linear DNA, and integrated at many sites. Cell 15, 1397-1410.

30 Hwang, L.H., and Gilboa, E. (1984). Expression of genes introduced into cells by retroviral infection is more efficient than that of genes introduced by DNA transfection. J. Virol. 50, 417-424.

35 Imblazano, A.N., Kwon, H., Green, M.R., Kingston, R.E. (1994). Nature 370, 481.

- 5 Ji, H., Moore, D.P., Blomberg, M.A., Braiterman, L.T.,
Voytas, D.F., Natsoulis, G., and Boeke, J.D. (1993).
Hotspots for unselected Ty1 transposition events on
yeast chromosome III are near tRNA genes and LTR
sequences. *Cell* 73, 1007-1018.
- 10 Kalpana, G.V., and Goff, S.P. (1993). Genetic analysis
of homomeric interactions of human immunodeficiency
virus type 1 integrase using the yeast two-hybrid
system. *Proc. Natl. Acad. Sci. USA* 90, 10593-10597.
- 15 Katz, R.A., Merkel, G., Kulkovsky, J., Leis, J., and
Skalka, A.M. (1990). The avian retroviral IN protein
is both necessary and sufficient for integrative
recombination in vitro. *Cell* 63, 87-95.
- 20 Khavari, P.A., Peterson, C.L., Tamkun, J.W., Mendel,
D.B., and Crabtree, G.R. (1993). BRG1 contains a
conserved domain of the SWI2/SNF2 family necessary for
normal mitotic growth and transcription. *Nature* 366,
170-174.
- 25 King, W., Patel, M., Lobel, L.I., Goff, S.P., and
Nguyen-Huu, C. (1985). Insertion mutagenesis of
embryonal carcinoma cells by retrovirus infection.
Science 228, 554-558.
- 30 Kozak, M. (1991). Structural features in eukaryotic
mRNAs that modulate the initiation of translation. *J.*
Biol. Chem. 266, 19867-19870.
- 35 Kruger, W., and Herskowitz, I. (1991). A negative
regulator of HO transcription, SIN1 (SPT2), is a
nonspecific DNA-binding protein related to HMG1. *Mol.*
Cell. Biol. 11, 4135-4146.
- Kwon, H. et al., *Nature* 370, 477 (1994)

Laurent, B., and Carlson, M. (1992). Yeast SNF2/SWI2, SNF5, and SNF6 proteins function coordinately with the gene-specific transcriptional activators GAL4 and Bicoid. *Genes Dev.* 6, 1707-1715.

5

Laurent, B.C., Treich, I., and Carlson, M. (1993). The yeast SNF2/SWI2 protein has DNA-stimulated ATPase activity required for transcriptional activation. *Genes Dev.* 7, 583-591.

10

Laurent, B.C., Treitel, M.A., and Carlson, M. (1990). The SNF5 protein of *saccharomyces cerevisiae* is a glutamine- and proline-rich transcriptional activator that affects expression of a broad spectrum of genes. *Mol. Cell. Biol.* 10, 5616-5625.

15

Laurent, B.C., Treitel, M.A., and Carlson, M. (1991). Functional interdependence of the yeast SNF2, SNF5, and SNF6 proteins in transcriptional activation. *Proc. Natl. Acad. Sci. USA* 88, 2687-2691.

20

Laurent, B.C., Yang, X., and Carlson, M. (1992). An essential *Saccharomyces cerevisiae* gene homologous to SNF2 encodes a helicase-related protein in a new family. *Mol. Cell. Biol.* 12, 1893-1902.

25

Luban, J., Alin, K.B., Bossolt, K.L., Humaran, T., and Goff, S.P. (1992). Genetic assay for multimerization of retroviral gag polyproteins. *J. Virol.*, 66, 5157-5160.

30

Luban, J., Bossolt, K.L., Franke, E.K., Kalpana, G.V., and Goff, S.P. (1993). Human immunodeficiency virus type 1 gag protein binds to cyclophilins A and B. *Cell* 73, 1067-1078.

35

Maniatis, T., Fritsch, E.F., and Sambrook, J. (1982).

Molecular cloning, a laboratory manual. (Cold Spring Harbor, N.Y.: Cold Spring Harbor).

- 5 Muchardt, C., and Yaniv, M. (1993). A human homologue of *Saccharomyces cerevisiae* SNF2/SWI2 and *Drosophila* brm genes potentiates transcriptional activation by the glucocorticoid receptor. *EMBO J.* 12, 4279-4290.
- 10 Natsoulis, G., Thomas, W., Roghmann, M.-C., Winston, F., and Boeke, J.D. (1989). Ty1 transposition in *Saccharomyces cerevisiae* is nonrandom. *Genetics* 123, 269-279.
- 15 Neigeborn, L., and Carlson, M. (1984). Genes affecting the regulation of SUC2 gene expression by glucose repression in *saccharomyces cerevisiae*. *Genetics* 108, 845-858.
- 20 Okabe, I., Bailey, L., Attree, O., Srinivasan, S., Perkel, J., Laurent, B., Carlson, M., Nelson, D., and Nussbaum, R. (1992). Cloning of human and bovine homologs of SNF2/SWI2: a global activator of transcription in yeast *S. cerevisiae*. *Nucleic Acids Research* 20, 4649-4655.
- 25 Peterson, C.L., and Herskowitz, I. (1992). Characterization of the yeast SWI1, SWI2, and SWI3 genes, which encode a global activator of transcription. *Cell* 68, 573-583.
- 30 Peterson, C.L., Dingwall, A., Scott, M.P., *Proc. Natl. Acad. Sci. USA* 91, 2905 (1994).
- 35 Pryciak, P.M., Sil, A., and Varmus, H.A. (1991). Retroviral integration into minichromosomes in vitro. *EMBO J.* 11, 769-780.

-47-

Rohdewohld, H., Weiher, H., Reik, W. Jaenisch, R., and Breindl, M. (1987). Retrovirus integration and chromatin structure: Moloney murine leukemia proviral integration sites map near DNase I-hypertensive sites. J. Virol. 61, 336-343.

Sandmeyer, S.B., Hansen, L.J., and Chalker, D.L. (1990). Integration specificity of retrotransposons and retroviruses. Ann. Rev. Genet. 24, 491-518.

Scherdin, U., Rhodes, K., and Breidl, M. (1990). Transcriptionally active genome regions are preferred targets for retrovirus integration. J. Virol. 64, 907-912.

Schwartzberg, P., Colicelli, J., and Goff, S.P. (1984). Construction and analysis of deletion mutations in the pol gene of Moloney murine leukemia virus: a new viral function required for productive infection. Cell 37, 1043-1052.

Shih, C.-C., Stoye, J.P., and Coffin, J.M. (1988). Highly preferred targets for retroviral integration. Cell 53, 531-537.

Shimotohno, K., and Temin, H.M. (1980). No apparent nucleotide sequence specificity in cellular DNA juxtaposed to retrovirus proviruses. Proc. Natl. Acad. Sci. USA 77, 7357-7361.

Shoemaker, C., Hoffman, J., Goff, S., and Baltimore, D. (1981). Intramolecular integration within Moloney murine leukemia virus DNA. J. Virol. 40, 164-172.

Varmus, H.E., Quintrell, N., and Ortiz, S. (1981). Retroviruses as mutagens: insertions and excision of a nontransforming provirus after expression of a

resident transforming provirus. Cell 25, 23-36.

5 Vijaya, S., Steffen, D.L., and Robinson, H.L. (1986).
Acceptor sites for retroviral integrations map near
DNase I-hypertensive sites in chromatin. J. Virol. 60,
683-692.

10 Weiss, R., Teich, N., Varmus, H., and Coffin, J.
(1984). RNA tumor viruses. (Cold Spring Harbor, N.Y.:
Cold Spring Harbor).

15 Winston, F., and Carlson, M. (1992). Yeast SNF/SWI
transcriptional activators and the SPT/SIN chromatin
connection. Topics in Genet. 8, 387-391.

Withers-Ward et al. (1994). Genes Dev. 8, 1473.

20 Yoshinaga, S.K., Peterson, C.L., Herskowitz, I., and
Yammamoto, K.R. (1992). Roles of SWI1, SWI2, and SWI3
proteins for transcriptional enhancement by steroid
receptors. Science 258, 1598-1604.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Goff, Stephen P.
Kalpana, Ganjam V.
- (ii) TITLE OF INVENTION: A cDNA Clone of the Human Ini-1 Gene Encoding
a Protein That Binds to the HIV-1 Integrase;
and Its Use in Antiviral Therapy
- (iii) NUMBER OF SEQUENCES: 4
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Cooper & Dunham
 - (B) STREET: 1185 Avenue of the Americas
 - (C) CITY: New York
 - (D) STATE: New York
 - (E) COUNTRY: U.S.A.
 - (F) ZIP: 10036
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.24
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: Not Yet Known
 - (B) FILING DATE: 24-May-1995
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 08/248,355
 - (B) FILING DATE: 24-May-1994
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: White Esq., John P.
 - (B) REGISTRATION NUMBER: 28,678
 - (C) REFERENCE/DOCKET NUMBER: 44301-A-PCT
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (212) 278-0400
 - (B) TELEFAX: (212) 391-0525

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1867 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: N
- (iv) ANTI-SENSE: N

-50-

(v) FRAGMENT TYPE: N-terminal
 (ix) FEATURE:

(A) NAME/KEY: CDS
 (B) LOCATION: 70..1225
 (D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GGCCCCGGCCCC CGCCCCAGCC CTCCTGATCC CTCGCAGCCCC GGCTCCGGCC GCCCCGCTCT	60
GCCGCGCGCA ATG ATG ATG ATG GCG CTG AGC AAG ACC TTC GGG CAG AAG	108
Met Met Met Met Ala Leu Ser Lys Thr Phe Gly Gln Lys	
1 5 10	
CCC GTG AAG TTC CAG CTG GAG GAC GAC GGC GAG TTC TAC ATG ATC GGC	156
Pro Val Lys Phe Gln Leu Glu Asp Asp Gly Glu Phe Tyr Met Ile Gly	
15 20 25	
TCC GAG GTG GGA AAC TAC CTC CGT ATG TTC CGA GGT TCT CTG TAC AAG	204
Ser Glu Val Gly Asn Tyr Leu Arg Met Phe Arg Gly Ser Leu Tyr Lys	
30 35 40 45	
AGA TAC CCC TCA CTC TGG AGG CGA CTA GCC ACT GTG GAA GAG AGG AAG	252
Arg Tyr Pro Ser Leu Trp Arg Arg Leu Ala Thr Val Glu Glu Arg Lys	
50 55 60	
AAA ATA GTT GCA TCG TCA CAT GGT AAA AAA ACA AAA CCT AAC ACT AAG	300
Lys Ile Val Ala Ser Ser His Gly Lys Lys Thr Lys Pro Asn Thr Lys	
65 70 75	
GAT CAC GGA TAC ACG ACT CTA GCC ACC AGT GTG ACC CTG TTA AAA GCC	348
Asp His Gly Tyr Thr Thr Leu Ala Thr Ser Val Thr Leu Leu Lys Ala	
80 85 90	
TCG GAA GTG GAA GAG ATT CTG GAT GGC AAC GAT GAG AAG TAC AAG GCT	396
Ser Glu Val Glu Glu Ile Leu Asp Gly Asn Asp Glu Lys Tyr Lys Ala	
95 100 105	
GTG TCC ATC AGC ACA GAG CCC CCC ACC TAC CTC AGG GAA CAG AAG GCC	444
Val Ser Ile Ser Thr Glu Pro Pro Thr Tyr Leu Arg Glu Gln Lys Ala	
110 115 120 125	
AAG AGG AAC AGC CAG TGG GTA CCC ACC CTG TCC AAC AGC TCC CAC CAC	492
Lys Arg Asn Ser Gln Trp Val Pro Thr Leu Ser Asn Ser Ser His His	
130 135 140	
TTA GAT GCC GTG CCA TGC TCC ACA ACC ATC AAC AGG AAC CGC ATG GGC	540
Leu Asp Ala Val Pro Cys Ser Thr Thr Ile Asn Arg Asn Arg Met Gly	
145 150 155	
CGA GAC AAG AAG AGA ACC TTC CCC CTT TGC TTT GAT GAC CAT GAC CCA	588
Arg Asp Lys Lys Arg Thr Phe Pro Leu Cys Phe Asp Asp His Asp Pro	
160 165 170	
GCT GTG ATC CAT GAG AAC GCA TCT CAG CCC GAG GTG CTG GTC CCC ATC	636
Ala Val Ile His Glu Asn Ala Ser Gln Pro Glu Val Leu Val Pro Ile	
175 180 185	
CGG CTG GAC ATG GAG ATC GAT GGG CAG AAG CTG CGA GAC GCC TTC ACC	684
Arg Leu Asp Met Glu Ile Asp Gly Gln Lys Leu Arg Asp Ala Phe Thr	
190 195 200 205	

-51-

TGG AAC ATG AAT GAG AAG TTG ATG ACG CCT GAG ATG TTT TCA GAA ATC	732
Trp Asn Met Asn Glu Lys Leu Met Thr Pro Glu Met Phe Ser Glu Ile	
210 215 220	
CTC TGT GAC GAT CTG GAT TTG AAC CCG CTG ACG TTT GTG CCA GCC ATC	780
Leu Cys Asp Asp Leu Asp Leu Asn Pro Leu Thr Phe Val Pro Ala Ile	
225 230 235	
GCC TCT GCC ATC AGA CAG CAG ATC GAG TCC TAC CCC ACG GAC AGC ATC	828
Ala Ser Ala Ile Arg Gln Gln Ile Glu Ser Tyr Pro Thr Asp Ser Ile	
240 245 250	
CTG GAG GAC CAG TCA GAC CAG CGC GTC ATC ATC AAG CTG AAC ATC CAT	876
Leu Glu Asp Gln Ser Asp Gln Arg Val Ile Ile Lys Leu Asn Ile His	
255 260 265	
GTG GGA AAC ATT TCC CTG GTG GAC CAG TTT GAG TGG GAC ATG TCA GAG	924
Val Gly Asn Ile Ser Leu Val Asp Gln Phe Glu Trp Asp Met Ser Glu	
270 275 280 285	
AAG GAG AAC TCA CCA GAG AAG TTT GCC CTG AAG CTG TGC TCG GAG CTG	972
Lys Glu Asn Ser Pro Glu Lys Phe Ala Leu Lys Leu Cys Ser Glu Leu	
290 295 300	
GGG TTG GGC GGG GAG TTT GTC ACC ACC ATC GCA TAC AGC ATC CGG GGA	1020
Gly Leu Gly Gly Glu Phe Val Thr Thr Ile Ala Tyr Ser Ile Arg Gly	
305 310 315	
CAG CTG AGC TGG CAT CAG AAG ACC TAC GCC TTC AGC GAG AAC CCT CTG	1068
Gln Leu Ser Trp His Gln Lys Thr Tyr Ala Phe Ser Glu Asn Pro Leu	
320 325 330	
CCC ACA GTG GAG ATT GCC ATC CGG AAC ACG GGC GAT GCG GAC CAG TGG	1116
Pro Thr Val Glu Ile Ala Ile Arg Asn Thr Gly Asp Ala Asp Gln Trp	
335 340 345	
TGC CCA CTG CTG GAG ACT CTG ACA GAC GCT GAG ATG GAG AAG AAG ATC	1164
Cys Pro Leu Leu Glu Thr Leu Thr Asp Ala Glu Met Glu Lys Lys Ile	
350 355 360 365	
CGC GAC CAG GAC AGG AAC ACG AGG CGG ATG AGG CGT CTT GCC AAC ACG	1212
Arg Asp Gln Asp Arg Asn Thr Arg Arg Met Arg Arg Leu Ala Asn Thr	
370 375 380	
GCC CCG GCC TGG T AACCAGCCCA TCAGCACACG GCTCCCACGG AGCATCTCAG	1265
Ala Pro Ala Trp	
385	
AAGATTGGGC CGCCTCTCCT CCATCTTCTG GCAAGGACAG AGGCGAGGGG ACAGCCCAGC	1325
GCCATCCTGA GGATCGGGTG GGGGTGGAGT GGGGGCTTCC AGGTGGCCCT TCCCCGTACA	1385
CATTCCATTT GTTGAGCCCC AGTCCTGCCC CCCACCCAC CCTCCCTACC CCTCCCCAGT	1445
CTCTGGGGTC AGGAAGAAAC CTTATTTTAG GTTGTGTTTT GTTTTGTATA GGAGCCCCAG	1505
GCAGGGCTAG TAACAGTTTT TAAATAAAAG GCAACAGGTC ATGTTCAAAA AAAAAAAT	1565
TTCTTAAATC TAGTGTCTTT ATTTCTTCTG TTACAATAGT GTTGCTTG TG TAAGCAGGTT	1625
AGAGTGCACA GTGTCCCCAA TTGTTCTCTG CACTGCAAAA CCAAATTAAA CAATCCCACA	1685

- 52 -

AAGAATTCTG ACATCAATGT GTTTCCTCA GTCAGTCTA TTTCAGATT CTAGAAGTTC 1745
 CTTTGTAAA ACTTGCCTTT AAAACTCTTC CTCCTAATGC CATCAGATCT CTTAACATTG 1805
 GCTCACTGTG GGATCTTTCC TCTTAGGTTG AATTTCTACG TGAATATCAA AGTGCCTTTT 1865
 TC 1867

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 385 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Met Met Met Ala Leu Ser Lys Thr Phe Gly Gln Lys Pro Val Lys
 1 5 10 15
 Phe Gln Leu Glu Asp Asp Gly Glu Phe Tyr Met Ile Gly Ser Glu Val
 20 25 30
 Gly Asn Tyr Leu Arg Met Phe Arg Gly Ser Leu Tyr Lys Arg Tyr Pro
 35 40 45
 Ser Leu Trp Arg Arg Leu Ala Thr Val Glu Glu Arg Lys Lys Ile Val
 50 55 60
 Ala Ser Ser His Gly Lys Lys Thr Lys Pro Asn Thr Lys Asp His Gly
 65 70 75 80
 Tyr Thr Thr Leu Ala Thr Ser Val Thr Leu Leu Lys Ala Ser Glu Val
 85 90 95
 Glu Glu Ile Leu Asp Gly Asn Asp Glu Lys Tyr Lys Ala Val Ser Ile
 100 105 110
 Ser Thr Glu Pro Pro Thr Tyr Leu Arg Glu Gln Lys Ala Lys Arg Asn
 115 120 125
 Ser Gln Trp Val Pro Thr Leu Ser Asn Ser Ser His His Leu Asp Ala
 130 135 140
 Val Pro Cys Ser Thr Thr Ile Asn Arg Asn Arg Met Gly Arg Asp Lys
 145 150 155 160
 Lys Arg Thr Phe Pro Leu Cys Phe Asp Asp His Asp Pro Ala Val Ile
 165 170 175
 His Glu Asn Ala Ser Gln Pro Glu Val Leu Val Pro Ile Arg Leu Asp
 180 185 190
 Met Glu Ile Asp Gly Gln Lys Leu Arg Asp Ala Phe Thr Trp Asn Met
 195 200 205
 Asn Glu Lys Leu Met Thr Pro Glu Met Phe Ser Glu Ile Leu Cys Asp

-53-

210	215	220
Asp Leu Asp Leu Asn Pro Leu Thr Phe Val Pro Ala Ile Ala Ser Ala		
225	230	235 240
Ile Arg Gln Gln Ile Glu Ser Tyr Pro Thr Asp Ser Ile Leu Glu Asp		
	245	250 255
Gln Ser Asp Gln Arg Val Ile Ile Lys Leu Asn Ile His Val Gly Asn		
	260	265 270
Ile Ser Leu Val Asp Gln Phe Glu Trp Asp Met Ser Glu Lys Glu Asn		
	275	280 285
Ser Pro Glu Lys Phe Ala Leu Lys Leu Cys Ser Glu Leu Gly Leu Gly		
	290	295 300
Gly Glu Phe Val Thr Thr Ile Ala Tyr Ser Ile Arg Gly Gln Leu Ser		
305	310	315 320
Trp His Gln Lys Thr Tyr Ala Phe Ser Glu Asn Pro Leu Pro Thr Val		
	325	330 335
Glu Ile Ala Ile Arg Asn Thr Gly Asp Ala Asp Gln Trp Cys Pro Leu		
	340	345 350
Leu Glu Thr Leu Thr Asp Ala Glu Met Glu Lys Lys Ile Arg Asp Gln		
	355	360 365
Asp Arg Asn Thr Arg Arg Met Arg Arg Leu Ala Asn Thr Ala Pro Ala		
	370	375 380
Trp		
385		

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 204 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: N

(iv) ANTI-SENSE: N

(v) FRAGMENT TYPE: N-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Ala Ser Gln Pro Glu Val Leu Val Pro Ile Arg Leu Asp Met Glu Ile
5 10 15
Asp Gly Gln Lys Leu Arg Asp Ala Phe Thr Trp Asn Met Asn Glu Lys
20 25 30

- 54 -

Leu Met Thr Pro Glu Met Phe Ser Glu Ile Leu Cys Asp Asp Leu Asp
 35 40 45
 Leu Asn Pro Leu Thr Phe Val Pro Ala Ile Ala Ser Ala Ile Arg Gln
 50 55 60
 Gln Ile Glu Ser Tyr Pro Thr Asp Ser Ile Leu Glu Asp Gln Ser Asp
 65 70 75 80
 Gln Arg Val Ile Ile Lys Leu Asn Ile His Val Gly Asn Ile Ser Leu
 85 90 95
 Val Asp Gln Phe Glu Trp Asp Met Ser Glu Lys Glu Asn Ser Pro Glu
 100 105 110
 Lys Phe Ala Leu Lys Leu Cys Ser Glu Leu Gly Leu Gly Gly Glu Phe
 115 120 125
 Val Thr Thr Ile Ala Tyr Ser Ile Arg Gly Gln Leu Ser Trp His Gln
 130 135 140
 Lys Thr Tyr Ala Phe Ser Glu Asn Pro Leu Pro Thr Val Glu Ile Ala
 145 150 155 160
 Ile Arg Asn Thr Gly Asp Ala Asp Gln Trp Cys Pro Leu Leu Glu Thr
 165 170 175
 Leu Thr Asp Ala Glu Met Glu Lys Lys Ile Arg Asp Gln Asp Arg Asn
 180 185 190
 Thr Arg Arg Met Arg Arg Leu Ala Asn Thr Ala Pro
 195 200

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 232 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: N
- (iv) ANTI-SENSE: N
- (v) FRAGMENT TYPE: N-terminal
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Asn Glu Thr Ser Glu Gln Leu Val Pro Ile Arg Leu Glu Phe Asp Gln
 5 10 15
 Asp Arg Asp Arg Phe Phe Leu Arg Asp Thr Leu Leu Trp Asn Lys Asn
 20 25 30
 Asp Lys Leu Ile Lys Ile Glu Asp Phe Val Asp Asp Met Leu Arg Asp

-55-

35 40 45
 Tyr Arg Phe Glu Asp Ala Thr Arg Glu Gln His Ile Asp Thr Ile Cys
 50 55 60
 Gln Ser Ile Gln Glu Gln Ile Gln Glu Phe Gln Gly Asn Pro Tyr Ile
 65 70 75 80
 Glu Leu Asn Gln Asp Arg Leu Gly Gly Asp Asp Leu Arg Ile Arg Ile
 85 90 95
 Lys Leu Asp Ile Val Val Gly Gln Asn Gln Leu Ile Asp Gln Phe Glu
 100 105 110
 Trp Asp Ile Ser Asn Ser Asp Asn Cys Pro Glu Glu Phe Ala Glu Ser
 115 120 125
 Met Cys Gln Glu Leu Glu Leu Pro Gly Glu Phe Val Thr Ala Ile Ala
 130 135 140
 His Ser Ile Arg Glu Gln Val His Met Tyr His Lys Ser Leu Ala Leu
 145 150 155 160
 Leu Gly Tyr Asn Phe Asp Gly Ser Ala Ile Glu Asp Asp Asp Ile Arg
 165 170 175
 Ser Arg Met Leu Pro Thr Ile Thr Leu Asp Asp Val Tyr Arg Pro Ala
 180 185 190
 Ala Glu Ser Lys Ile Phe Thr Pro Asn Leu Leu Gln Ile Ser Ala Ala
 195 200 205
 Glu Leu Glu Arg Leu Asp Lys Asp Lys Asp Arg Asp Thr Arg Arg Lys
 210 215 220
 Arg Arg Gln Gly Arg Ser Asn Arg
 225 230

-56-

What is claimed is:

1. An isolated nucleic acid encoding an integrase interactor 1 gene (ini-1).
- 5 2. The isolated nucleic acid of claim 1, wherein the nucleic acid is DNA encoding the integrase interactor 1 gene that is free of one or more introns present in genomic DNA.
- 10 3. The DNA of claim 1 labelled with a detectable moiety selected from a group consisting of a fluorescent label, a radioactive atom, and a chemiluminescent label.
- 15 4. Isolated DNA of claim 1.
5. The isolated DNA of claim 4, wherein the DNA is cDNA.
- 20 6. The isolated DNA of claim 4, wherein the DNA is genomic DNA.
- 25 7. The isolated DNA of claim 2 labelled with a detectable moiety selected from a group consisting of a fluorescent label, a radioactive atom, and a chemiluminescent label.
8. A replicable vector comprising the nucleic acid of claim 1.
- 30 9. The replicable vector of claim 8, wherein the nucleic acid is free of introns.
10. A plasmid of claim 8.
- 35 11. A plasmid of claim 9.

-57-

12. A host cell containing the vector of claim 8.
13. A host cell containing the vector of claim 9.
- 5 14. The host cell of claim 12, wherein the cell is a eukaryotic cell.
15. The host cell of claim 12, wherein the cell is a bacterial cell.
- 10 16. The host cell of claim 13, wherein the cell is a eukaryotic cell.
- 15 17. The host cell of claim 13, wherein the cell is a bacterial cell.
18. A purified polypeptide comprising naturally-occurring ini-1.
- 20 19. The purified polypeptide of claim 18, wherein the polypeptide is the product of prokaryotic or eukaryotic expression of an exogenous DNA sequence.
- 25 20. The purified polypeptide of claim 19, wherein the exogenous DNA sequence is a cDNA sequence.
21. The purified polypeptide of claim 18, wherein the ini-1 is human ini-1.
- 30 22. The purified polypeptide of claim 19, wherein the exogenous DNA sequence is a genomic DNA sequence.
- 35 23. The purified polypeptide of claim 19, wherein the exogenous DNA sequence is carried on an autonomously replicating DNA plasmid or viral vectors.

-58-

24. The purified polypeptide of claim 18, possessing part or all the amino acid sequence of human ini-1 as shown in Figure 4 or any naturally occurring allelic variant thereof.
- 5
25. The purified polypeptide of claim 18 which has in vivo biological activity of naturally occurring ini-1.
- 10
26. The purified polypeptide of claim 18 which has in vitro biological activity of naturally occurring ini-1.
- 15
27. The purified polypeptide of claim 18 further characterized by being covalently associated with a detectable label substance.
- 20
28. A method of determining whether a compound is capable of interfering with the formation of a complex between a retrovirus integrase protein and an ini-1 protein, which comprises:
- 25
- a) incubating the compound with an appropriate ini-1 affinity fusion protein and the retrovirus integrase protein;
- 30
- b) contacting the incubate of step (a) with an appropriate affinity medium under conditions so as to bind the ini-1 affinity protein complex, if such a complex forms; and
- 35
- c) measuring the amount of the ini-1 affinity protein complex formed in step (b) so as to determine whether the compound is capable of interfering with

-59-

the formation of the complex between the retrovirus integrase protein and the ini-1 protein.

- 5 29. The method of claim 28, wherein the retrovirus integrase protein is HIV-1 IN.
30. The method of claim 28, wherein the affinity fusion protein is GST-ini-1
- 10 31. The method of claim 28, wherein the affinity medium is glutathione-agarose beads.
32. The method claim 28, wherein the amount of the ini-1 affinity protein complex formed is determined using monoclonal antibodies.
- 15 33. The method of claim 28, wherein the amount of the ini-1 affinity protein complex formed is determined using polyclonal antibodies.
- 20 34. The method of claim 28, wherein the ini-1 affinity protein complex is bound to the affinity medium.
- 25 35. The method of claim 34, wherein the ini-1 affinity protein complex is purified and removed from the affinity medium and the amount of integrase protein is determined.
- 30 36. A method for determining whether a compound is capable of interfering with the formation of a complex between a retrovirus integrase protein and an ini-1 protein, which comprises:
- 35 a) incubating the compound with an appropriate retrovirus integrase affinity fusion protein and the ini-1

-60-

protein;

- 5 b) contacting the incubate of step (a) with
 an appropriate affinity medium under
 conditions so as to bind the retrovirus
 integrase affinity protein complex, if
 such a complex forms; and
- 10 c) measuring the amount of the retrovirus
 integrase affinity protein complex
 formed in step (b) so as to determine
 whether the compound is capable of
 interfering with the formation of the
15 complex between the retrovirus integrase
 protein and the ini-1 protein.
37. The method of claim 36, wherein the affinity
 medium is glutathione-agarose beads.
- 20 38. The method claim 36, wherein the amount of the
 affinity protein complex formed is determined
 using monoclonal antibodies.
- 25 39. The method claim 36, wherein the amount of the
 affinity protein complex formed is determined
 using polyclonal antibodies.
- 30 40. The method of claim 36, wherein the retrovirus
 integrase affinity protein complex is bound to the
 affinity medium.
- 35 41. The method of claim 40, wherein the retrovirus
 integrase affinity protein complex is purified and
 removed from the affinity medium and an amount of
 ini-1 protein is determined.
42. A method of disrupting a retrovirus life cycle in

-61-

5 a cell which comprises contacting the cell with a compound which is capable of disrupting a retrovirus integrase protein-ini-1 protein interaction so as to thereby disrupt the retrovirus life cycle.

43. The method of claim 41, wherein the compound contacting the cell is a soluble ini-1 fragment.
- 10 44. The method of claim 41, wherein the compound contacting the cell is a soluble HIV-1 IN fragment.
- 15 45. The method of claim 41, wherein the compound contacting the cell is a chemical molecule.
- 20 46. A method of disrupting a retrovirus life cycle in a mammal which comprises administering to the mammal a compound which is capable of disrupting a retrovirus integrase protein-ini-1 protein interaction so as to thereby disrupt the retrovirus life cycle.
- 25 47. The method of claim 46, wherein the compound administered to the mammal is a soluble ini-1 fragment.
- 30 48. The method of claim 46, wherein the compound administered to the mammal is a soluble HIV-1 IN fragment.
49. The method of claim 46, wherein the compound administered to the mammal is a chemical molecule.

1/9

FIGURE 1




FIGURE 2A



FIGURE 2B






FIGURE 2C



3/9

FIGURE 3



4/9

FIGURE 4


```

-69 GCC CCG GCC CCG CCC CAG CCC TCC TGA TCC CTC GCA GCC CGG CTC -25
-24 CCG CCG CCC GCC TCT GCC GCC GCA ATG ATG ATG ATG GCG CTG AGC 21
-8 AAG ACC TTC GGG CAG AAG CCC GTG M M M M A L S 7
8 K T F G O K P V K TTC CAG CTC GAG GAC GAC 66
67 GCG GAG TTC TAC ATG ATC GGC TCC CAG GTG GGA AAC TAC CTC CGT 22
23 G E F Y M I G S E V G N Y L R 111
112 ATG TTC CGA GGT TCT CTC TAC AAG AGA TAC CCC TCA CTC TGG AGG 37
38 M F R G S L Y K R Y P S L M R 156
157 CGA CTA GCC ACT GTG GAA GAG AGG AAG AAA ATA GTT GCA TCG TCA 52
53 R L A T V E R K K I V A S S 201
202 CAT GGT AAA AAA ACA AAA CCT AAC ACT AAG GAT CAC GGA TAC ACC 67
68 H G K K T K P N T K D H G Y T 246
247 ACT CTA GCC ACC AGT GTG ACC CTG TTA AAA GCC TCG GAA CTG GAA 82
83 T L A T S V T L K A S E V E 291
292 GAG ATT CTG GAT GGC AAC GAT GAG AAG TAC AAG GCT GTG TCC ATC 97
98 E I L D G N D E K Y K A V S I 336
337 AGC ACA GAG CCC CCC ACC TAC CTC AGG GAA CAG AAG GCC AAG AGG 112
113 S T E P P T Y L R E O K A K R 381
382 AAC AGC CAG TGG GTA CCC ACC CTG TCC AAC AGC TCC CAC CAC TTA 127
128 N S O M V P T L S N S S H H L 426
427 GAT GCC GTG CCA TGC TCC ACA ACC ATC AAC AGG AAC CGC ATG GGC 142
143 D A V P C S T T I N R N R M G 471
472 CGA GAC AAG AAG AGA ACC TTC CCC CTT TGC TTT GAT GAC CAT GAC 157
158 R D K K R T F P L C F D H D 516
517 CCA GCT GTG ATC CAT GAG AAC CCA TCT CAG CCC GAG GTG CTG GTC 172
173 P A V I H E N A S O P E V L V 561
562 CCC ATC CCG CTG GAC ATG GAG ATC GAT GCG CAG AAG CTG CGA GAC 187
188 P I R L D H E I D G O K L R D 606
607 GCC TTC ACC TGG AAC ATG AAT GAG AAG TTG ATG ACC CCT GAG ATG 202
203 A F T W N M N E K L M T P E M 651
652 TTT TCA GAA ATC CTC TGT GAC GAT CTG GAT TTG AAC CCG CTG ACC 217
218 P S E I L C D D L D L N P L T 696
697 TTT GTG CCA GCC ATC GCC TCT GCC ATC AGA CAG CAG ATC GAG TCC 232
233 F V P A I A S A I R O O I E S 741
742 TAC CCC ACG GAC AGC ATC CTG GAG GAC CAG TCA GAC CAG CGC GTC 247
248 Y P T D S I L E D O S D Q R V 786
787 ATC ATC AAG CTG AAC ATC CAT GTG GGA AAC ATT TCC CTG GTG GAC 262
263 I I K L N I H V G N I S L V D 831
832 CAG TTT GAG TGG GAC ATG TCA GAG AAG GAG AAC TCA CCA GAG AAG 277
278 O F E M D H S E K E N S P E K 876
877 TTT GCC CTG AAG CTG TGC TCG CAG CTG GCG TTG GCG GGG GAG TTT 292
293 F A L K L C S E L G L G G E F 921
922 GTC ACC ACC ATC GCA TAC AGC ATC CCG GGA CAG CTG AGC TGG CAT 307
308 V T T I A Y S I R G O L S N H 966
967 CAG AAG ACC TAC GCC TTC AGC GAG AAC CCT CTG CCC ACA GTC GAG 322
323 Q K T Y A F S E N P L P T V E 1011
1012 ATT GCC ATC CCG AAC ACG GGC GAT GCG GAC CAG TGG TGC CCA CTG 337
338 I A I R N T G D A D O M C P L 1056
1057 CTG GAG ACT CTG ACA GAC GCT GAG ATG GAG AAG AAG ATC CGC GAC 352
353 L E T L T D A E H E K K I R D 1101
1102 CAG GAC AGG AAC ACG AGG CCG ATG ACG CGT CTT GCC AAC ACG GCC 367
368 O D R N T R R M R R L A N T A 1146
1147 CCG GCC TGG TAA CCA GCC CAT CAG CAC ACC GCT CCC ACG GAG CAT 382
383 P A W ... 1191
1192 CTC AGA AGA TTG GGC CGC CTC TCC TCC ATC TTC TGG CAA GGA CAG 397
1237 AGG CGA GGG GAC AGC CCA GCG CCA TCC TGA GGA TCG GGT GGG GGT 1236
1282 GGA GTG GGG GCT TCC AGG TGG CCC TTC CCG GTA CAC ATT CCA TTT 1281
1327 GTT GAG CCC CAG TCC TGC CCC CCA CCC CAC CCT CCC TAC CCC TCC 1326
1372 CCA GTC TCT GGG GTC AGG AAG AAA CCT TAT TTT AGG TTG TGT TTT 1371
1417 GTT TTG TAT AGG AGC CCC AGG CAG GGC TAG TAA CAG TTT TTA AAT 1416
1462 AAA AGC CAA CAG GTC ATG TTC AAAAAAAAAA 1461
1507 TTT CTT CTG TTA CAA TAG TGT TGC TTG TGT AAG CAG GTT AGA GTG 1506
1552 CAC AGT GTC CCC AAT TGT TCC TGG CAC TGC AAA ACC AAA TTA AAC 1551
1597 AAT CCC ACA AAG AAT TCT GAC ATC AAT GTG TTT TCC TCA GTC AGG 1596
1642 TCT ATT TCA AGA TTC TAG AAG TTC CTT TTG TAA AAC TTG CCT TTA 1641
1687 AAA CTC TTC CTC CTA ATG CCA TCA GAT CTC TTA ACA TTG GCT CAC 1686
1732 TGT GGG ATC TTT CCT CTT AGG TTG AAT TTC TAC GTG AAT ATC AAA 1731
1777 GTC CCT TTT TC 1787

```

5/9

FIGURE 5A



6/9

FIGURE 5B

ini-1 180 ..ASQPEVLVPIRILDMELDGGK..LRDAFTNNMNEKLMTPMSEILCDDLD
 snf5 451 ..NETSEQLVPIRILEFDQDRDRFFLRDTLLNNKNKDKLIKIEDFVDDMLRDYR
 <-----region I----->

228 LNPLI...FVPAIASAIRQRIEESYPTDSILE.....DQSDQRVITKLNIT
 501 FEDATREQHIDTICQSICQIQEFQGNPYIELNQDRLGGDDLIRIKLDT
 <-----region II----->

269 HVGNISSLDQFEWDMSEKENSPKFAKLCSELGLGGEFVITIAYSIRGQ
 551 VVGQNLIDQFEWDISNSDNCPEEFAESMCQELFPGFIVTIAIHSIREQ
 <-----region II----->

319 LSWHQKTYAFSEN.....PLPTVEIAIRNTGDAQWCP
 601 VHMYSLSALLGYNFDGSAIEDDIRSRMLPTITLDDVYRPAESKIFTP

352 LLETLTDAEMKKIRDQDRNTRRMRRLANTAP.. 383
 651 NLQISAAELERLDKDKDRTRRKRRQGRSNR.. 682
 <-----region III----->

7/9

FIGURE 6A




FIGURE 6B





FIGURE 6C



SUBSTITUTE SHEET (RULE 26)

8/9

FIGURE 7A





FIGURE 7B



SUBSTITUTE SHEET (RULE 26)

FIGURE 8A




FIGURE 8C





FIGURE 8D



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US95/06683

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : 424/93.21; 435/7.1, 69.1, 172.3; 530/350; 536/23.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/93.21; 435/7.1, 69.1, 172.3; 530/350; 536/23.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, AIDSLINE, MEDLINE, WPIDS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Annu. Rev. Biochem., Volume 63, issued 1994, (Katz et al), "THE RETROVIRAL ENZYMES", pages 133-173.	1-49
A	Cell, Volume 73, issued 18 June, 1993, (Luban et al.), "Human Immunodeficiency Virus Type 1 Gag Protein Binds to Cyclophilins A and B", pages 1067-1078.	1-49
A, P	Science, Volume 266, issued 23 December 1994, (Kalpana et al.), "Binding and Stimulation of HIV-1 Integrase by a Human Homolog of Yeast Transcription Factor SNF5", pages 2002-2006.	1-49

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be part of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"A" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

17 AUGUST 1995

Date of mailing of the international search report

28 AUG 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

Jeffrey S. Parkin, Ph.D.

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/06683

A. CLASSIFICATION OF SUBJECT MATTER:
IPC (6):

A01N 63/00; A61K 48/00; C07H 21/02, 21/04; C07K 1/00, 14/00, 17/00; C12N 15/00; C12P 21/06; G01N 33/53

Form PCT/ISA/210 (extra sheet)(July 1992)*

This Page is inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLORED OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images
problems checked, please do not report the
problems to the IFW Image Problem Mailbox**